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ABSTRACT
The in vitro and in vivo release characteristics of a controlled-release hydrogel 
prostaglandin polymer pessary were compared during an eight hour observation period in 24 
patients using a pessary designed to release PGE2 1.0mg/hr. and in 25 patients using a pessary 
designed to release PGE^ O.bmg/hr. PGE2 release rate in vitro followed a linear and quadratic 
pattern while release rate in vivo was described by a quadratic pattern. The differences were 
predominately due to less hydrogel swelling of the pessary in vivo. Pre-soaking the polymer 
pessary in saline prior to vaginal insertion to increase hydrogel swelling did not influence 
release characteristics in vivo, but PGE2 release was increased by amniotomy. No differences 
in PGE2 release rate or absorption across the vaginal epithelium were demonstrated for 
polymer pessaries of different release profiles and PGE2 release was not related to the degree 
of cervical ripening. During the course of these studies technical difficulty was experienced 
with pessary removal.
Clinical benefits in cervical ripening were assessed by treating 33 primiparae with an 
unfavourable cervix (Bishop score < 6) with a polymer pessary designed to release PGE2
0.6mg/hr. on the evening before planned induction. Controlled release of PGE2 was not 
associated with an exclusively cervical effect as 52% of those treated commenced labour 
during the ripening process. Those who required a second treatment prior to the onset of 
labour were randomly allocated to receive an amniotomy and oxytocin titration or a further 
polymer pessary. The second treatment to delivery interval was shorter for those receiving an 
amniotomy and oxytocin titration and seven out of eight patients who received a second 
polymer pessary later required oxytocin augmentation. These results suggest that there is little 
benefit to be gained from repeated prostaglandin treatments.
There was a 3.7% incidence of excessive uterine activity associated with the use of the 
polymer pessary in studies conducted in this thesis. In all cases removal of the pessary resulted 
in a return to normal uterine activity. The results of this research suggest that some cases of
rapid labour could be avoided by removal of the pessary following amniotomy or spontaneous 
rupture of membranes but an adequate retrieval mechanism is necessary.
Prostaglandin-induced cervical ripening under tocolytic cover was investigated in a 
double blind trial with 60 nulliparae requiring induction of labour whose modified Bishop 
score was < 6. Women received either 8mg salbutamol or an identical placebo orally, 30 
minutes before vaginal administration of 2mg prostaglandin E2 gel. Women in the salbutamol 
group experienced less uterine activity over the subsequent 12 hours compared with those 
given placebo and fewer (35%) commenced labour compared with the placebo group (62%). 
However the change in cervical score was significantly less in the salbutamol group (mean 3.0 
sd 3.1) than the placebo group (mean 5.8, sd 3.2) and the prostaglandin to delivery interval in 
the salbutamol group (mean 26.1 h, sd 6.49 h) was significantly longer than in the placebo 
group (mean 19.3 h sd 7.95 h). The first stage of labour lasted > 10 h in 11 women in the 
salbutamol group, compared with 5 in the placebo group. Side effects attributable to 
salbutamol occurred in 10% of the treated women but in none of their fetuses and fetal 
outcome was satisfactory and similar in both groups. These findings suggest that salbutamol 
can suppress prostaglandin-induced uterine activity during cervical ripening which could be an 
advantage in induction of labour where a planned delivery is preferred. However the poorer 
outcome of labour in salbutamol treated women mitigates against this approach.
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During this time the physiological and pharmacological effects of prostaglandins were 
also being investigated, and much of the early work was concentrated on the reproductive 
system. In 1957, Pickles discovered the presence of a smooth muscle stimulant in menstrual 
fluid (Pickles 1957) which was later identified as prostaglandin (Pickles et al 1965). The 
actions of prostaglandins on the smooth muscle of the fallopian tube were also reported 
(Sandberg et al 1963) and following the discovery of prostaglandins in amniotic fluid (Karim 
1966), it was demonstrated that prostaglandin-rich extracts of amniotic fluid obtained during 
labour increased the intensity of uterine activity (Karim & Devlin 1967). With this knowledge, 
Karim and colleagues used prostaglandin therapeutically for the first time when they 
demonstrated that intravenous infusions of P<3P^u induced labour in women at term, and 
abortion at earlier gestations if used in higher doses (Karim et al 1968, Karim & Filshie 
1970a). At about the same time it was shown that PGE2 possessed similar properties (Embrey 
1969, Karim & Filshie 1970b) and subsequent refinements in the use of prostaglandins have 
firmly established their role in labour induction and abortion.
With the knowledge that prostaglandins were clinically useful therapeutic agents came 
the need for widescale synthesis. Biosynthesis of prostaglandins (by incubation of arachidonic 
acid with homogenates of sheep seminal vesicles) could not meet the demands for the 
production of prostaglandin commercially and total chemical synthesis was subsequently 
developed by Corey (1971) and by Axen et al (1972). Since then, many prostaglandin 
analogues have also been produced in an attempt to overcome the chemical and metabolic 
instability of the natural compounds.
In 1971 Vane reported on the use of aspirin as an inhibitor of prostaglandin synthesis 
(Vane 1971): this not only implicated prostaglandins in the inflammatory process but also 
provided another means of studying the physiological functions of prostaglandins. During the 
next few years the discovery of thromboxane (Hamberg et al 1975) and prostacyclin 
(Moncada et al 1976) opened up a further area of research into the derivatives of arachidonic
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acid, but it was the discovery of the leucotrienes (Samuelsson et al 1980) that brought about 
the realisation that prostaglandins represented only a small part of the arachidonic cascade 
system. More recently the epoxygenase and lipo-oxygenase pathways have been elucidated 
(Capdevilla et al 1982, Malle et al 1987) and while attention is predominately focused on this 
area of eicosanoid research, the physiological and pharmacological actions of prostaglandins 
and their analogues are still being investigated. Prostacyclin has been used to inhibit platelet 
aggregation during renal dialysis and mesoprostal, a synthetic analogue of PGE% has been 
used to promote healing of gastric and duodenal ulcers. In reproductive physiology the search 
continues for the most effective and safe method of using prostaglandin to induce labour and 
abortion and the role of prostaglandins in cellular metabolism during pregnancy and labour 
remains an exciting area of research.
1.2 NOMENCLATURE AND STRUCTURE
Prostaglandins are oxygenated, unsaturated hydroxy fatty acids which form part of a 
group of 20 carbon chain compounds collectively known as eicosanoids. Eicosanoids include 
products of the cyclo-oxygenase, lipo-oxygenase and epoxygenase pathways. Prostaglandins, 
thromboxane, and prostacyclin are all derived from the cyclo-oxygenase pathway and are 
referred to as "prostanoids". They differ structurally from other eicosanoids in that they all 
possess a ring structure. Each prostaglandin contains a pentane ring, while thromboxane 
contains an oxane ring and prostacyclin a double ring. The skeleton structure of each 
prostanoid is based on that of the theoretical prostanoic acid which is illustrated in Figure 1.
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Figure 1 The chemical relationship between prostanoic acid 
and thromboxane, prostacyclin, PGE, PGFoc and 
PGD.
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Each group of naturally occurring prostanoids is referred to by a letter from A to I 
according to the composition of the ring structure and the number of substituents on different 
carbon atoms (Figure 1). Each prostanoid is further designated a numerical subscript from one 
to three which depends on the number of double bonds on the alkyl side chains. The structure 
of PGE2 with two double bonds is shown in Figure 2. PGF is also assigned an a or B subscript 
to indicate differences in the configuration of the hydroxy group at C9, although the B form 
does not exist naturally.
1.3 BIOSYNTHESIS OF PGE2
The biosynthesis of PGE2 occurs through a pathway that forms part of a series of 
cellular processes known as the arachidonic acid cascade, which is also responsible for the 
formation of all eicosanoids. This is illustrated in Figure 3.
Eicosanoids are all ultimately derived from two essential fatty acids, -linoleic and 
linolenic acid, which must be supplied by food intake. These essential fatty acids may be 
converted to polyunsaturated fatty acids by chain elongation and desaturation, a process which 
takes place in microsomal membranes (Nugteren 1962,1963). Three eicosanoid precursors, 
arachidonic acid, Di- homo- -linolenic acid, and eicopentanoic acid are formed by such 
mechanisms and subsequently stored mainly as phospholipids in the cell wall, but also as 
cholesterol esters and triglycerides. Arachidonic acid is the most important of these fatty 
acids, and gives rise to prostaglandins containing two double bonds in their alkyl side chains. 
Di-homo- -linolenic acid and eicopentanoic acid lead to the formation of prostaglandins with 
one and three double bonds in their alkyl side chains respectively.
22
Figure 2 The molecular structure of PGE2
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Figure 3 The Arachidonic Acid Cascade
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Arachidonic acid is liberated from phospholipids in a reaction catalysed by 
phospholipase A^ and then converted to the cyclic endoperoxides in two steps: a 
cyclo-oxygenase reaction yields prostaglandin G% (PGG2), which is then reduced to form 
prostaglandin H2(PGH2). Both reactions are catalysed by prostaglandin endoperoxide 
synthetase which has cyclo-oxygenase and peroxidase activity (Miyamoto et al 1976). The 
endoperoxides can be converted non-enzymatically predominately to PGE2 or enzymatically 
to any prostanoid.
Two other enzyme pathways are known to be part of the arachidonic acid cascade, the 
lipo-oxygenase and the epoxygenase pathways. Arachidonic acid may react with 
lipo-oxygenase to form hydroperoxy-eicoatetraenoic acid (HPETE), which can then be 
transformed into various leucotrienes. Alternatively, the action o f cytochrome P-450 on 
arachidonic acid leads to the formation of epoxy-eicosatrienoic acids.
1.4 METABOLISM OF PGE2
Early metabolic studies on experimental animals showed rapid inactivation of infused 
PGE2 with 95% removed in one circulation through the lungs and 70% removed in one 
passage through the portal circulation (Ferreira & Vane 1967). Subsequent intravenous 
infusion experiments in humans have demonstrated similar findings with 95% tritium labelled 
PGE2 being metabolically cleared in 1.5 minutes (Hamberg & Samuelsson 1971). The major 
metabolite that results from this inactivation is 13,14-dihydro-l5-keto-PGE2 (Figure 4) which 
is more stable than its parent compound, having a half life of approximately 8 minutes. Its 
formation is catalysed by two enzymes with oxidation of the C l5 hydroxyl group by 
15-hydroxy prostaglandin reductase followed by reduction of the 13,14, double bond by 
13,14 prostaglandin reductase. Both enzymes occur in most tissues, but are particularly active 
in the liver, kidney and lungs (Granstrom & Kumlin 1987).
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Figure 4 Metabolism of PGEg
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13,14-dihydro-15-keto-PGE2 may be further degraded by several mechanisms prior to 
excretion in urine. One or two stages of B oxidation may occur resulting in a dinor or tetranor 
derivative. W oxidation of this compound results in a hydroxyl or carboxyl group at the w end 
of the molecule. Non enzymatic dehydration to PGA and PGB derivatives is also possible. 
Reduction of the 9-keto group into PGF compounds has been demonstrated, while PGF 
compounds may also be converted into PGE metabolites by dehydrogenation of the 9 
hydroxyl group, although this probably does not occur in humans (Granstrom & Kumlin 1987 
-PI 62). The principal urinary metabolite in humans is 11 
-hydroxy-9,15-diketo-2,3,4,5-tetranorprostane-l,20-dioic acid, although other metabolites 
have been identified.
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SECTION 2: MECHANISMS OF LABOUR
2.1 INTRODUCTION
Spontaneous labour involves important changes in cervical compliance and uterine 
smooth muscle function which are activated by prostaglandins. Their production is controlled 
by a series of hormonal events that probably depend on both mother and fetus. While our 
knowledge of these events is poor in some species, including the human, it is clearly 
documented in others, such as the sheep.
The fundamental difference between sheep and human parturition is the ability of the 
former to produce placental 17 a  hydroxylase (Liggins 1983) which is one of two enzymes 
responsible for the conversion of progesterone to oestrogens. Its activity and that of C 17-20 
lyase (Steele et al 1976) are low throughout most of pregnancy but levels increase about ten 
days prior to parturition stimulated by a marked elevation in fetal cortisol production. The 
subsequent fall in progesterone and rise in oestrogens is followed by increased prostaglandin 
concentrations in maternal and fetal plasma (Thorbum & Challis 1979).
The importance of fetal cortisol and the fetal pituitary adrenal axis was established in a 
series of observations made in the late 1960s. It was found that lesions of the hypothalamus or 
pituitary gland of the fetal lamb led to a marked prolongation of gestation (Liggins et al 1967), 
while stimulation of the fetal adrenals by ACTH, cortisol (Liggins 1968), or dexamethasone 
(Liggins 1969) was followed by premature parturition. The rapid increase in fetal cortisol 
levels before birth (Bassett & Thorbum 1969) may be due to increased fetal adrenal 
sensitivity to ACTH secreted by the fetal pituitary gland, which itself has increased sensitivity 
to stimulation by corticotrophic-releasing factor (Challis 1985).
Vaginal distension in the ewe in late pregnancy (Flint et al 1975) and administration of 
oxytocin (Mitchell et al 1976) have also been associated with increased synthesis of
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in maternal circulating oestrogens (Parker et al 1982). It is unclear what stimulates the 
increase but it may be related to increased adrenal sensitivity to fetal ACTH. An alternative 
source of oestrogens may be provided from oestrone sulphate, whose levels have been noted 
to increase in amniotic fluid in the last weeks of pregnancy (Challis 1985).
2.3 THE EFFECTS OF PROGESTERONE WITHDRAWAL
In 1956 Csapo suggested that uterine activity was suppressed in pregnancy by 
progesterone and reactivated by progesterone withdrawal (Csapo 1956). This "progesterone 
block" theory was supported by studies of the effects of luteectomy. Progesterone synthesis is 
thought to be transferred from the corpus luteum to the placenta during early pregnancy 
(Csapo 1969). Removal of the corpus luteum in humans before the luteo-placental shift has 
been shown to result in a dramatic fall in serum progesterone, producing increased uterine 
responsiveness to oxytocics (Csapo et al 1973). Abortion in early pregnancy has been induced 
by luteectomy with an associated fall in progesterone levels (Csapo & Pulkkinen 1978), 
although abortion did not occur with the prolonged use of epostane, a 313 hydroxysteroid 
dehydrogenase inhibitor, in women undergoing mid trimester terminations when similarly low 
levels of progesterone were achieved (Pattison et al 1984).
The "progesterone block" theory was later expanded to postulate that uterine activity 
was controlled by interplay between the suppressor, progesterone, and the stimulant, 
prostaglandin. This has been referred to as the "see-saw" theory of the regulatory mechanism 
of pregnancy (Csapo 1975), and it is supported by evidence from other studies with 
antiprogesterones. For example, epostane has been shown to sensitise the myometrium to 
oxytocics (Selinger et al 1987) and termination of first trimester pregnancies has been 
achieved with RU 38,486, a progesterone receptor competitor, in combination with 
prostaglandins (Hill et al 1990).
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At present it is believed that progesterone levels in maternal or fetal blood probably do 
not fall prior to the onset of spontaneous labour (Casey & MacDonald 1988). However, in 
vitro work has shown that human fetal membranes at term are capable of progesterone 
production which may be inhibited locally by unconjugated oestrogens and DHEAS so that 
progesterone withdrawal need not be associated with a change in circulating progesterone 
levels (Mitchell et al 1982a). Inhibition of progesterone may also influence B adrenergic 
receptor expression by the myometrium (Neulen & Breckfold 1994). This might also reduce 
further B adrenergic induced placental progesterone production.
2.4 THE ROLE OF OXYTOCIN
The success of pharmacological doses of oxytocin in induction and augmentation of 
labour suggest that endogenous secretion may also play an important role in the initiation of 
parturition. Attempts at studying endogenous oxytocin production were at first hampered by 
inadequate assay techniques and the first sensitive radioimmunoassay capable of detecting 
oxytocin in umbilical cord plasma was not developed until 1970 (Chard et al 1970). Several 
studies have since reported that oxytocin levels rise in maternal plasma during gestation 
(Kumareson et al 1974, Dawood et al 1978a, Vasicka et al 1978, Sellers et al 1981a), but 
opinion is divided as to whether levels rise during labour. Kumareson and colleagues and 
Sellers and colleagues failed to detect any rise in maternal plasma levels of oxytocin associated 
with labour. Dawood and workers reported a significant increase from the first to the second 
stage of labour and Vasicka and colleagues reported an oxytocin surge in association with 
cervical dilatation and vaginal distension. The disparity in these results may be related to the 
assays used or differences in oxytocinase inhibition techniques (Thornton et al 1989). 
Alternatively they may be due to spurt release of oxytocin. Surges of oxytocin have been 
noted in the first and second stages of labour (Gibbens et al 1972), during cervical dilatation 
and vaginal distension (Vasicka et al 1978), and during surgical induction of labour by 
amniotomy (Chard & Gibbens 1983).
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The fetus may be able to produce oxytocin which could play a role in human 
parturition It has been shown that there is a significant difference between plasma oxytocin 
levels in fetal umbilical cord arterial and venous plasma at delivery with higher levels in the 
artery (Dawood et al 1978b, Sellers et al 1981a). Arterial levels were also higher after 
spontaneous labour compared to delivery by elective caesarean section. Dawood et al (1978b) 
were able to detect oxytocin in fetal urine.
Oxytocin receptors have been identified in the human uterus during pregnancy and at 
parturition (Fuchs et al 1982, Fuchs et al 1984). The concentration of these receptors was 
found to increase during pregnancy, reaching maximal concentration during labour. No 
differences in the affinity of the receptors was noted at any stage of gestation. These findings 
would support the observations made by Caldeyro-Barcia & Sereno (1961) that the sensitivity 
of the uterus to oxytocin increases throughout gestation.
Prostaglandin production in vitro in human decidua, amnion and myometrium is 
increased by oxytocin (Fuchs et al 1981). However, PGF metabolite levels in vivo only appear 
to increase during oxytocin infusion provided that labour is established (Husslein et al 1981, 
Fuchs et al 1983) so that the rise in PGF metabolites is either responsible for the progress of 
labour, or result from it.
2.5 THE ROLE OF PROSTAGLANDINS
There is now overwhelming evidence that prostaglandins are involved in human 
parturition. PGE^ and PGF^u can stimulate myométrial strips in vitro (Embrey & Morrison 
1968), and both prostaglandins can induce uterine contractions at any stage of gestation and 
are used for induction of abortion and labour. PGE^ and PGF^u have been shown to 
accumulate in amniotic fluid during labour (Karim & Devlin 1967, Keirse & Turnbull 1973, 
Keirse et al 1974) and concentrations of PGF^u are higher in women in spontaneous labour 
than in those whose labour is induced with oxytocin (Keirse et al 1974). Inhibitors of
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prostaglandin synthesis have been shown to delay labour in animal studies (Aiken 1972) and 
prolonged intake of aspirin, a prostaglandin synthase inhibitor, can prolong human pregnancy 
(Lewis & Schulman 1973, Collins & Turner 1975). Further evidence for prostaglandin 
involvement in parturition comes from studies reporting their increased synthesis and 
metabolism during pregnancy and labour, and these are now reviewed in more detail.
Arachidonic Acid Mobilisation
Arachidonic acid is stored mainly as glycerophospholipid in intra-uterine tissues and 
accounts for 9% to 26% of the total fatty acid content of fetal membranes, placenta, umbilical 
cord, decidua and myometrium (Keirse 1985). In the amnion, more than 45% of arachidonic 
acid is stored as phosphatidylethanolamine (Okita et ai 1982) and during the early stages of 
labour there are significant changes in the arachidonic acid composition of this phospholipid as 
well as that of phosphatidylinositol. This suggests that there is selective mobilisation of 
arachidonic acid from the fetal membranes in early labour (Okita et at 1982, Bleasdale & 
Johnston 1984). However the total fatty acid content of phospholipid does not alter as 
arachidonic acid released by the membranes is replaced by palmitic acid. The total release of 
arachidonic acid is more than would be required for prostaglandin production in labour.
Liberation of arachidonic acid from phosphatidylethanolamine requires phospholipase 
A2. In the case of phosphatidylinositol three enzymes are required: phospholipase C, 
diaglycerol lipase, and monoglycerol lipase (Bleasdale & Johnston 1984). The activities of 
phospholipase A% and phospholipase C increase during gestation (Okazaki et al 1981), but 
there appears to be no difference in the activities of these enzymes before and after labour. If 
selective mobilisation of arachidonic acid increases during labour, the activity of these 
enzymes must be influenced in some other way. The function of both enzymes depends on 
calcium and it has been suggested that either the sensitivity of the enzymes to calcium may 
increase or the cytosolic calcium concentration itself may increase. There is some evidence for 
both mechanisms. Some substances such as platelet activating factor can influence the
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concentration of calcium in amnion (Roukin et al 1983), and hydrolysis of phosphatidylinositol 
by phospholipase C is greatly increased in the presence of polyamines, which have been found 
in amniotic fluid (Russell et al 1978).
Utilisation of Arachidonic Acid
Arachidonic acid liberated from phospholipid stores may be utilised in any part of the 
arachidonic acid cascade including the lipoxygenase and epoxygenase pathways, but there is 
evidence that mobilisation is directed towards increased prostaglandin production in late 
pregnancy and spontaneous labour. Cyclooxygenase, which is necessary for the conversion of 
arachidonic acid to prostaglandin endoperoxides, is known to be present in all uterine tissues 
in late pregnancy (Christenson & Green 1983) and pregnant myometrium contains three times 
more Cyclooxygenase than non pregnant myometrium (Moonen et al 1984). Conversion of 
the endoperoxides to primary prostaglandins may occur enzymatically depending on the 
amount of prostaglandin endoperoxide available (Keirse 1985) or non-enzymatically. In vitro 
experiments have demonstrated that chorion and decidua are capable of producing PGE2 and 
PGF2(x but amnion appears to be the principal site of increased PGE2 synthesis in labour 
(Okazaki et al 1981, Lopez-Bemal et al 1987a). PGE2 derived from the amnion must be 
transferred across the chorion and decidua, which both possess 15-hydroxyprostaglandin 
dehydrogenase, in order to stimulate myométrial activity. It has been demonstrated in vitro 
that radioactively labelled PGE2 can pass from amnion to decidua without metabolism (Nakla 
et 1986). PGE2 in decidua may also be converted to PGF2C1 by the action of 9-keto-reductase, 
and PGF2C1 may pass freely from decidua to amnion.
Other factors have been shown to influence PGE production in vitro but it is unclear at 
what level in the arachidonic acid cascade they act. Relaxin has been localised in human 
chorion and decidua (Bryant-Greenwood et al 1987) and inhibits PGE production by the 
amnion in vitro but favours its production in labour (Lopez-Bemal et al 1987b). It was 
suggested that loss of the inhibitory activity may be due to down regulation of receptor sites
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or to a superimposed stimulatory effect on the PG synthatase system. PGE production by the 
human amnion in vitro can also be inhibited by ovine prolactin (Tyson et al 1985), which 
suggests that endogenous prolactin produced predominately by human decidual tissue 
(Bryant-Greenwood et al 1987) may also have a paracrine function in prostaglandin 
regulation.
Metabolism Of Prostaglandins During Pregnancy And Labour
The ability of uterine tissues to increase prostaglandin synthesis during pregnancy and 
labour is balanced by the ability to increase prostaglandin metabolism. In vitro observations of 
prostaglandin dehydrogenase (PGDH) and 13,14-prostaglandin reductase activity have 
demonstrated that most prostaglandin metabolism in the pregnant uterus takes place in the 
fetal membranes and placenta (Keirse & Turnbull 1975). Further studies have localised 
chorion as the principal site (Okazaki et al 1981, Skinner & Challis 1985). Concentrations of 
placental PGDH have been shown to increase in early gestation to levels consistent with those 
at term (Keirse et al 1985), but changes in PGDH activity have not been associated with the 
onset of labour (Keirse et al 1976).
Metabolite Studies
The rate of prostaglandin production in pregnancy and labour can be detected by 
measurement of the 13,14-dihydro-15-keto-prostaglandin derivative in the peripheral 
circulation. Assay of the PGF metabolite shows no change in pregnancy but a significant rise 
in spontaneous labour (Lacritz et al 1978, Mitchell et al 1978). This increase appears to be 
related to the onset and progress of labour (Sellers et al 1981b, Fuchs et al 1983). 
Concentrations also rise within five minutes of amniotomy (Sellers et al 1980, 1981b) and 
remain elevated for at least 30 minutes, although levels may decline again if labour does not 
become established. The rise in PGF metabolites after amniotomy is not associated with a 
change in plasma oxytocin levels, so that a local mechanism for prostaglandin release might
35
exist (Sellers et al 1980), although the increase might be related to changes in the 
concentration of oxytocin receptors (Husslein et al 1983).
Assay of the PGE metabolite is unreliable as 13,14 dihydro-15-PGE is itself unstable, 
but it can be converted to a stable bicyclo PGE^ compound by alkahnization of plasma 
(Fitzpatrick et al 1980), which has led to the development of a direct radioimmunoassay for 
bicyclo PGEM (Demers et al 1983). Using this assay, plasma concentrations of PGEM have 
not been observed to rise during pregnancy, although they may be higher than in non-pregnant 
women (Mitchell et al 1982b, Husslein & Sinzinger 1984, Brennecke et a/ 1985). During 
labour PGEM concentrations have been noted to increase by some (Mitchell et al 1982b, 
Husslein & Sinzinger 1984) but not by others (Brennecke et al 1985), and there does not 
appear to be a rise in PGEM in relation to amniotomy (Husslein & Sinzinger 1984). The 
reasons for these disparities are not clear.
2.6 CONTROL OF MYOMETRIAL FUNCTION
Smooth muscle contraction is based on the interaction of actin and myosin. During 
pregnancy this interaction has to be largely prevented whereas in labour the forces generated 
by the resultant myométrial contraction have to be strong enough to dilate the cervix. The 
neural and hormonal influences which control parturition ultimately govern coupling of actin 
and myosin.
The interaction between actin and myosin is thought to take place once the myosin 
light chain has been phosphorylated (Huszar & Naftolin 1984). Phosphorylation requires the 
enzyme myosin light chain kinase which is activated by binding to calcium as a 
calcium-calmodium complex and inhibited by cyclic AMP mediated phosphorylation.
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Calcium levels are regulated by the cell membrane which contains calcium channels 
and by the actions of storage vesicles such as the sarcoplasmic reticulum and mitochondria. 
Progesterone is thought to promote calcium sequestration in storage vesicles while 
prostaglandins and oxytocin inhibit the process or mobilise intracellular calcium from the 
sarcoplamic reticulum through secondary messengers (Carsten & Miller 1987). The 
mechanism by which prostaglandin influences intracellular second messengers is thought to 
involve its interaction at the cell membrane with a specific receptor which is coupled to a 
guanine nucleotide regulatory N protein (Smith et al 1987). Binding of prostaglandin to its 
receptor causes dissociation of the N protein which activates phospholipase C which 
hydrolyses phosphatidylinositol 4,5 diphosphate to diacylglycerol and inositol 1,4,5 
triphosphate. Inositol 1,4,5 triphosphate binds to receptors on the sarcoplasmic reticulum 
stimulating calcium release.
Changes in concentration and affinity of receptors may also play a role in the control of 
myométrial function. In vitro studies have demonstrated that the pregnant myometrium and 
cervix contain high-affinity PGE binding sites. However the concentration of these receptors 
is higher in the non-pregnant state than at term (Giannopoulos et al 1985, Adelantado et al 
1988), which may provide a protective mechanism against uterine contractility in pregnancy. 
No difference in the affinity of receptors for PGE between pregnant and non-pregnant 
myometrium was observed in one study (Adelantado et al 1988), but there was a lower PGE 
binding affinity in cervical tissue when compared to the myometrium. It has been suggested 
that high-affinity binding sites may be responsible for the contracting effects of PGE while 
low-affinity binding sites may mediate the cervical ripening effects.
Pregnant myometrium and cervix also contain PGP^u receptor sites, but the affinity of 
prostaglandin receptors for PGE is about ten times higher than that for PGF (Schillinger & 
Prior 1976, Giannopoulos et al 1985, Adelantado et al 1988). This may partly explain the 
greater potency of PGE in stimulating uterine contractility. The PGF2a receptors are probably 
low-affinity sites which may bind both PGE and PGF2a (Giannopoulos et al 1985, Adelantado
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et al 1988), although in one study it was demonstrated that PGF2u had a higher affinity for its 
own receptor than PGE (Hofmann *?/ al 1983). It has been suggested that low-affinity PGF2a 
binding sites are unlikely to be specific receptors, and that any action of PGF2a in the human 
uterus may be mediated through interaction with PGE receptor sites (Schillinger & Prior 
1976).
Generation of co-ordinated myométrial contractions are facilitated by gap junction 
formation between cells. These are areas of low resistance to electrical impulses which may 
allow synchronisation of contractions. Animal studies have demonstrated that gap junction 
frequency is low during pregnancy, increases at term and is highest during labour. They begin 
to disappear within 24 hours of delivery (Garfield 1984). Gap junction formation is thought to 
be stimulated by oestrogens, prostaglandins and inhibition of progesterone.
2.7 CONTROL OF CERVICAL RIPENING
The cervix is composed of connective tissue and a cellular component comprising 
smooth muscle, fibroblasts and macrophages. Connective tissue is made up of collagen and 
connective tissue matrix (ground substance) containing glycoproteins which consist of 
glycosaminoglycans, principally dermatan sulphate, bound to a protein core. During the last 
few weeks of pregnancy these structural components undergo dramatic changes in preparation 
for labour. The cervix becomes softer with enhanced dilatation and effacement due to an 
increase in water content, a reduction in collagen and an increase in glycosaminoglycans 
(Danforth et al 1974). The composition of glycosaminoglycans also changes with an increase 
in keratin sulphate and hyaluronate and a decrease in chondroitin and dermatan sulphates (Von 
Maillot e / a / 1981).
Endocrine phenomena are probably responsible for these changes, and oestrogen, 
progesterone, relaxin and prostaglandins may all be involved. Histological studies of the
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uterine cervix in pregnant patients at term have shown increased oedema, vascularity and 
vacuolization following administration of high doses of oestradiol (Pinto et al 1965), and 
oestrogens may increase collagenase activity (Mochizuki et al 1978) as well as modulate the 
synthesis of glycosaminoglycans (Uldbjerg et al 1983). Progesterone administration has been 
shown to diminish collagen breakdown in cervical explants from non-pregnant women 
following progesterone administration (Hillier & Wallis 1981), and cervical dilatation can be 
induced by antiprogesterones (Ullmann & Dubois 1988). Purified porcine relaxin has been 
shown to cause a dissolution of collagen bundles and an apparent increase in ground substance 
in the cervices of pregnant rabbits near term (MacLennan et al 1985), but human plasma levels 
of relaxin have been measured throughout pregnancy and appear to be lower in the 3rd 
trimester (Eddie et al 1986). Prostaglandin production by the human cervix has been 
demonstrated in vitro (Ellwood et al 1980) but its effects remain unclear. Animal studies have 
demonstrated increased collagenase production by cervical fibroblasts (Goshowaki et al 1988) 
but opinion is divided as to whether this occurs in human cervical tissue (Szaley et al 1981, 
Rath et al 1987). Effects on the glycosaminoglycan content (Rath et al 1987) and on cervical 
smooth muscle may also be important. An increase in glycosaminoglycan content has been 
demonstrated in cervical biopsies following treatment with intracervical PGE2 gel although 
this finding has not been supported by in vitro studies (Norman et al 1993).
PGE2 may mediate its effects on cervical ripening through cytokines. Animal studies 
have demonstrated an infiltration of polymorphonuclear granulocytes, macrophages and mast 
cells into the cervix following cervical ripening (Chwatz 1994). This may result from an 
increase in local vascular permeability stimulated by PGE^ (Kelly RW 1994). Interleukins may 
also be involved. Interleukin 1 beta levels in amniotic fluid have been shown to increase during 
mechanical cervical ripening.(George et al 1993) and interleukin 8 can activate granulocytes 
with subsequent release of collagenase (Calder AA 1997).
The effects of myométrial activity on cervical change are complex. Myométrial 
contractions increase uterine wall tension which promotes cervical dilatation. (Gee 1994).
However an increase in cervical compliance will lower wall tension as well as promote 
dilatation. The overall effect of myométrial activity and cervical ripening is to enhance 
progress of labour. The relationship between uterine activity and cervical compliance has been 
termed the cervical augmentation/attenuation of pressure (CAP) effect (Gee 1994). The CAP 
effect has particular relevance to the effects of prostaglandins which both promote cervical 
ripening and uterine activity.
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SECTION 3: METHODS OF LABOUR INDUCTION
3.1 INTRODUCTION
One of the earliest references to labour induction was made in the second century A.D. 
by Soranus of Ephesus who mentioned the use of manual dilatation of the cervix for women 
with pelvic deformity (Davey 1980, Thieiy ef al 1989). However it was not until the late 
eighteenth century that one method, low amniotomy, gained widespread recognition 
throughout Europe as a successful means of inducing labour before term. Referred to as the 
English method, it was first used by Dr. MacCauley to induce preterm labour in a linen 
draper’s wife with cephalopelvic disproportion and was later described by Denman (Denman 
1785). The physiological mechanism responsible for the success of this method was unclear 
until the association between amniotomy and stimulation of endogenous prostaglandin was 
realised (Sellers e/a/1981b).
High amniotomy was introduced at the beginning of the nineteenth century (Hamilton 
1836) as a means of overcoming the frequency of intra-uterine infection that was associated 
with low amniotomy. Later other methods of induction which preserved the membranes 
became more popular and these have been summarised by Fasbender (1906). The Bougie 
Method was apparently described by Mampe in 1838 but it was advocated by Krause in 1855 
and subsequently became known as the Krause Method. It involved passing a soft rubber 
bougie through the cervix to lie between the membranes and the uterine wall. Breast massage, 
hot vaginal douches and extraamniotic injections of fluid were all used and soon after the 
introduction of the Krause method, in 1862, Tamier introduced his metreunyter or 
intra-uterine bag. Later the metreunyters of Braun, Muller, Champetier de Ribes and Vorhees 
were also used although this method never gained popularity with British Obstetricians. Many 
other attempts at induction focused on the cervix. Cervical insertion of sponge tents was 
employed by Brunninghausen in 1820, rubber bags by Barnes in 1861 and tampons by Kehrer
in 1888.
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The introduction of ergot into obstetric practice followed the publication of a letter by 
Steam in 1808 (Steam 1808). An association between eating bread made from rye infected 
with an ergot fungus and worsening labour pains had been known since the 16th century and 
Steam suggested its cautious use in women with abnormally slow labours. However the drug 
was often mis-used and resulted in several cases of fetal death and uterine rupture. Since the 
end of the 19th century ergot has been little used in labour induction, but its role in post 
partum haemorrhage is now firmly established.
Watson's regime of medical induction was introduced at the beginning of the twentieth 
century and this involved the use of castor oil, taking a hot bath and later, if labour was not 
established, quinine sulphate (Watson 1922). Castor oil and heat were both thought to induce 
uterine contractions and quinine had originally been used as an abortificient. It was later 
dropped from the regime due to concern that it might be toxic to the fetus. However the use 
of posterior pituitary extract was subsequently added to the regime following a number of 
observations on its use in obstetrics. In 1906 Dale had demonstrated that posterior pituitary 
extract stimulated uterine muscle (Dale 1906) and Blair Bell was the first obstetrician to use 
this quality in the treatment of post-partum haemorrhage (Bell 1909). In 1928 Kamm and his 
colleagues isolated oxytocin from the posterior pituitary gland (Kamm et al 1928) and later 
Stein recommended its use in labour induction (Stein 1934), giving rise to the so-called 
Watson-Stein regime. In subsequent years pituitary extracts were administered intramuscularly 
for labour induction, and although preparations were standardised, the uterine response was 
often erratic and led to hyperstimulation. Further advances were made when administration 
was controlled by using a dilute solution infused intravenously (Theobald et al 1948). Over the 
next decade the chemical structure of oxytocin was elucidated (Du Vigneaud et al 1953), and 
commercial synthesis followed.
A resurgence of the use of high amniotomy in the early twentieth century followed the 
work of Drew-Smythe. He developed his own instrument, the Drew-Smythe catheter, which
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was used to perform a high amniotomy well away from the cervix thereby reducing the risk of 
infection, and retaining the bag of forewaters. This was thought to be the main hydrostatic 
wedge and essential for the normal progress of the first stage of labour (Smythe 1949).
Current methods of labour induction are based on refinements that have been made in 
the use of oxytocin, and on the discovery of the oxytocic properties of prostaglandins, while 
still employing the well known benefits of amniotomy.
3.2 AMNIOTOMY
Amniotomy results in release of endogenous prostaglandins (Sellers et al 1981b, 
Sellers 1985) and can lead to successful induction of labour. However the failure rate of this 
procedure alone is approximately 20% and is related to parity and the ripeness of the cervix 
(Turnbull & Anderson 1967), Low amniotomy is currently preferred to high amniotomy, 
which may damage the fetus, although there are situations where high amniotomy may be 
useful such as in cases of polyhydramnios, or where the presenting part has not engaged. 
There is no evidence to suggest that high amniotomy reduces the risks of intra-uterine 
infection.
3.3 OXYTOCIN AND AMNIOTOMY
The intravenous route is now established as the safest and most reliable method of 
administering oxytocin to induce and augment labour. Initially there was disagreement on the 
optimum dosage regime (Theobald 1959, Ryan 1960), with a tendency to favour very low 
doses which were increased gradually to ensure safety. In 1968 Turnbull and Anderson 
suggested the idea of oxytocin titration starting with a low dose and increasing the amount in 
short intervals until strong regular uterine contractions were established (Turnbull & Anderson 
1968a). The optimum dose depended on the strength and frequency of contractions, thereby 
allowing for individual variatioh in the response to oxytocin. This provided an efficient and
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safe method of induction but its success depended both on parity and initial cervical score. 
Labour outcome was further improved by combining oxytocin titration with amniotomy 
(Turnbull & Anderson 1968b). This resulted in a fall in the incidence of Caesarean section and 
a great reduction in the time between amniotomy and delivery when compared to the use of 
oxytocin titration alone. Several different infusion systems were later devised to control the 
rate of oxytocin administration as accurately as possible (Francis et al 1970, Butterworth 
1974, Carter & Steer 1980). Alternative methods of administration were also evaluated in an 
attempt to overcome the inconvenience of an intravenous drip for both patient and midwife. 
Intramuscular administration was abandoned because of the inability to control the effects of 
oxytocin following absorption (Carey 1959). The intranasal route was thought to be both 
effective and safe by some (Hendricks & Gabel 1960, Clement et al 1962), but others 
considered it uncomfortable for the patient and difficult to control. The use of buccal oxytocin 
was received with greater enthusiasm (Elstein & Wright 1963, Spence & Chalmers 1964) but 
the tablets had to be held in the buccal cavity until they dissolved, which could take as long as 
an hour and sometimes resulted in local soreness (Br Med J 1964). This method was also 
criticised for lack of control (Best 1964) but it continued to be used by obstetricians for
several years.
Uterine sensitivity to oxytocin increases throughout pregnancy (Cibils 1972) and there 
is considerable variation in individual response at term (Embrey 1975). Hyperstimulation of 
contractions can occur (Liston & Campbell 1974) and may cause fetal distress and uterine 
rupture (Daw 1973). However the short plasma half-life of oxytocin of three to four minutes 
(Gonzalez-Panizza et al 1961) and the fine control that is possible when it is given by 
intravenous titration, may lead to a reduced frequency of these dangerous side effects.
The association between the use of oxytocin and neonatal jaundice has been observed 
by several investigators (Calder et al 1974a, Chalmers et al 1976, Chew 1977, D Souza et al
1979). The explanation for this association has not been fully established and may include a 
direct effect of oxytocin, artificial interruption of pregnancy or relative immaturity of bilirubin
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conjugation in the neonate (Calder et al 1974a). The antidiuretic properties of oxytocin can 
result in maternal hyponatraemia with an associated fall in fetal plasma sodium concentration 
(Burt et al 1969, Schwartz & Jones 1978). This may lead to both maternal and neonatal 
convulsions, and particular care must be exercised when considering oxytocin use in women 
already at risk of fluid overload such as thosewith hypertension or renal disease. _____
3.4 PROSTAGLANDINS
The first clinical work using PGB^ in labour induction was reported by Bygdeman and 
colleagues (Bygdeman et al 1968) in a study observing the effects of PGE ^  and PGE j  infused 
intravenously to patients in midpregnancy and at term. Both compounds stimulated uterine 
activity at a threshold dose of 4-8pg/min at term, but the authors concluded that PGE 
compounds were unsuitable for labour induction because of the small difference between the 
dose increasing uterine motility and that causing hypertonus. This was based on the fact that 
uterine tone increased to 22mm Hg and 14mm Hg in one case out of five treated with PGE} 
and in one case out of seven treated with PGE^ when either compound was infused at a rate 
of 4pg/min. At about the same time the first study on labour induction with PGE^o was 
published (Karim et al 1968) and during the following year successful induction was reported 
in seven out of eight patients at term using an intravenous infusion ofPGE^ lasting 20 to 75 
minutes at a rate of 2-6 pg/min (Embrey 1969). A significant increase in amplitude and 
frequency of contractions was associated with the infusions without causing appreciable 
hypertonus, although in one case a transient rise in uterine tone occurred at a rate of 8pg/min, 
but quickly disappeared when the infusion rate was reduced. A further 13 out of 14 patients 
were successfully induced at term using a continuous infusion of PGE^ until labour was 
established (Embrey 1969), and larger trials using a similar regime soon followed (Karim et al 
1970c, Beazley et al 1970). In the latter study it was suggested that a variable rate of infusion 
would be more appropriate as the uterine threshold to PGE^ was not predictable and comment 
was also made on the lack of gastrointestinal side effects, which were found to be more 
common using PGF2a (Brown et al 1973). However inflammatory reactions at infusion sites
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were not uncommon, and in early comparative studies using PGE2 or intravenous oxytocin 
no clear advantage of either method was demonstrated (Beazley & Gillespie 1971, Craft et al 
1971, Anderson et al 1972, Naismith et al 1973, Brown et al 1973). These generally 
disappointing results led to the investigation of more desirable routes of administration.
The oral route was the first to be adopted and an early study reported successful 
induction in 79 out of 80 women at or near term, using an aqueous solution containing 0.5mg 
PGE2 given orally and repeated every 2 hours until labour was established (Karim & Sharma 
1971a). The authors commented on the convenience of oral administration both to patients 
and medical staff and similar methods were later reported by others (Craft 1972, Barr & 
Naismith 1972). It was subsequently found that a low dose regime of oral PGE2 0.5mg hourly 
given for a maximum of 10 hours was as effective as a larger dose of l.Omg hourly in inducing 
labour but with less gastrointestinal side effects (Friedman et al 1975). Since then many 
studies with oral PGE2 have adopted this dose at the start of treatment in labour induction 
(Tsakok et al 1975, Gordon-Wright et al 1979, Westergaard et al 1983, Sommeil 1987).
The vaginal route of administration was investigated as early as 1971 (Karim & 
Sharma 1971b) when five women at term were induced using PGE2 2mg vaginally in 
repeated doses until labour was established. It was concluded that this method was 
unacceptable to patients when compared to other routes. However, the success of 
extraamniotic prostaglandins in mid-trimester abortions soon led to the investigation of this 
route for labour induction (Calder & Embrey 1973, Miller & Mack 1974), and it appeared to 
be particularly effective in cases where the cervix was unripe, an observation which was also 
supported by later work (Calder et al 1974b). The technique involved infusion of PGE2 
extra-amniotically via a catheter passed through the cervical canal. The importance of 
inducibility features had been known for some time (Bishop 1964, Friedman et al 1966) but 
developments over the next few years led to the entirely new concept of cervical ripening 
prior to labour induction by the use of a single dose of PGE2 injected extra-ammotically 
(Shepherd et al 1976, Calder et al 1977). Calder and colleagues treated primigravidae with a
46
modified Bishop score of less than four using a single dose of extra-amniotic PGE2 ranging 
from 0.24-0.48mg PGE2 in viscous gel. Results were very impressive with patients 
experiencing a 25% reduction in the length of induced labour, a fall in the incidence of 
maternal pyrexia and fetal distress, an improvement in neonatal condition of the infants as 
measured by Apgar scores and a reduced Caesarean section rate compared with a control 
group being induced by amniotomy and oxytocin augmentation. The technique was simplified 
further by using a single dose of PGE2 in cellulose gel administered into the posterior vaginal 
fornix (MacKenzie & Embrey 1977). In both studies the need for formal induction and 
oxytocin augmentation was significantly reduced. Similar observations have since been made 
in several studies using a single dose of prostaglandin either vaginally (Buchanan et al 1984, 
Curet & Gauger 1988), or a smaller dose intracervically (Laube et al 1986, Kristofferson et al 
1986, Bernstein et al 1987), a route particularly popular in the Netherlands.
Following the success of the vaginal administration of PGE2 for cervical ripening, this 
method was soon extended to include primigravidae and multigravidae with all ranges of 
cervical score using different doses of PGE2 in cellulose gel (MacKenzie & Embrey 1978). It 
was found that 65% of primigravidae and 83% of multigravidae with a favourable cervix 
commenced labour after PGE2 alone, clearly demonstrating that a single dose of PGE2 
administered vaginally was an effective means of labour induction, an observation which has 
since been confirmed by others (Shepherd et al 1981, Kennedy et al 1982a).
The use of prostaglandins has now been firmly incorporated into clinical obstetric 
practice following the development of improved techniques of administration, and the 
discovery of their advantages in cervical ripening. Prostaglandins are currently routinely given 
by the oral or vaginal routes for labour induction, while the intracervical or vaginal routes are 
preferred for cervical ripening.
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3.5 OTHER METHODS
Mechanical methods for cervical ripening have been reintroduced in the last 30 years, 
and include the use of balloon catheters inserted into the extraamniotic space (Embrey & 
Mollison 1967) or intracervically (Atad el al 1997), laminaria tents (Lackritz et al 1979), 
lamicel, a synthetic polyvinyl sponge (Johnson et al 1985) and breast stimulation (Elliot & 
Flaherty 1984). A greater understanding of the complex physiological mechanisms involved in 
the initiation of labour has also led to the use of other medical agents in cervical ripening in the 
last 10 years. DHAS has successfully been used to ripen the unfavourable cervix between 38 
and 40 weeks gestation when given by the intravenous route to nulliparae and multiparae 
(Mochizuki et al 1978, Sasaki et al 1982) supporting the later finding that cervical changes 
preceding the onset of labour were associated with an elevation of maternal DHAS levels 
(Zuidema et al 1986). The use of oestradiol given by different routes of administration has had 
variable success. In one comparative study, extraamniotic ethinyloestradiol and PGE2 were 
found to be equally effective in cervical ripening (Stewart et al 1981), but in a further 
double-blind randomised controlled trial ethinyloestradiol given by the same route was no 
more effective than placebo (Peedicayil et al 1989). Intramuscular oestradiol was found to 
have no detectable effect on the unripe cervix when compared to controls, and no synergistic 
effect when used in combination with oral PGE2 (Luther et al 1980). Relaxin has been shown 
to influence cervical changes when given vaginally (Evans et al 1983), or intracervically 
(MacLennan et al 1986). Initial reports on the safety of vaginal recombinant human relaxin in 
cervical ripening were also encouraging (Bell et al 1993), but it was ineffective as a cervical 
ripening agent in a recent multicentre double blind placebo controlled trial (Brennard et al 
1997). Misoprostol, a prostaglandin analogue, has recently been suggested as an effective 
agent for cervical ripening and labour induction (Wing et al 1995, Rodrigues et al 1998). 
Finally, following their success in termination of early pregnancy, progesterone antagonists 
have been considered in labour induction (Frydman et al 1992) but more studies are required 
to assess their effects.
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SECTION 4: THE ROLE OF PGE2IN CERVICAL RIPENING 
AND LABOUR INDUCTION
4.1 ADVANTAGES
4.1.1 CERVICAL RIPENING
The most important predictor of successful labour induction is the state of the cervix 
(Embrey & Anselmo 1962, Turnbull & Anderson 1968a), which may be determined by a 
digital assessment of cervical dilatation, consistency, effacement, position, and descent of the 
fetal presenting part (Bishop 1964, Friedman et al 1966, Calder et al 1974b). Any attempt at 
induction for women with a closed, firm and long or "unfavourable cervix" is more likely to be 
associated with a long labour and high rates of intra-uterine infection and operative delivery, 
as far more uterine work is required than in situations where the cervix is already dilated, soft 
and effaced or "favourable". These changes may be promoted by the local application of 
prostaglandins. Several studies, often involving control groups, have demonstrated a 
reduction in the length of induced labour, a reduction in the need for oxytocin augmentation or 
a reduction in the incidence of Caesarean section when PGE2 is applied either vaginally 
(MacKenzie & Embrey 1977, Prins <?/ al 1983, Buchanan et al 1984, Curet & Gauger 1988, 
Rayburn et al 1988) or intracervically (Nimrod et al 1984, Laube et al 1986, Kristofferson et 
al 1986, Bernstein et al 1987). The use of sequential doses of PGE2 (Prins et al 1986, 
Mainprize et al 1987) has not been found to be more effective than a single dose of PGE2 
with a similar period of observation. Meta-analysis of data suggests that oral prostaglandins, 
intravenous oxytocin infusions, or the local application of oestrogens are of little benefit for 
cervical ripening (Keirse & Van Oppen 1989a, Keirse 1993), and no additional benefits have 
been observed by the sequential use of oestradiol and PGE2 (Williams et al 1988). Very few 
trials have compared mechanical methods of cervical ripening with the use of vaginal 
prostaglandins but analysis of the available data suggests that prostaglandins are more likely
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to be associated with an improvement in cervical score and the onset of spontaneous labour 
(Keirse & Van Oppen 1989a).
4.1.2 LABOUR INDUCTION
When prostaglandins administered by the oral or vaginal routes are compared to the 
use of oxytocin and amniotomy for routine induction of labour, both methods appear equally 
effective. Labour outcome was similar when the use of oral PGE2 was compared to buccal 
oxytocin (Mathews et ai 1976, Lykkesfeldt & Osier 1981, Westergaard et a / 1983), or 
intravenous oxytocin (Miller et al 1975, Secher et al 1981) either with or without an 
amniotomy at the start of the induction. However a significantly higher frequency of 
gastrointestinal side effects was seen in those women treated with PGE2 (Westergaard et al 
1983). When compared to intravenous oxytocin and amniotomy, administration of vaginal 
prostaglandins has been associated with a reduced incidence of epidural analgesia, post partum 
haemorrhage (MacKenzie et al 1981, Kennedy et al 1982b) and a reduced incidence of 
Caesarean sections (MacKenzie & Embrey 1978, Hefiii & Lewis 1980). Other comparative 
studies on patients with favourable induction features have shown little difference between the 
two approaches whether PGE2 is administered vaginally (Macer et al 1984, Ekman et al 
1986) or intracervically (Ulmsten et al 1979). Meta-analysis suggests that less women remain 
undelivered 24 hours following induction when treated with prostaglandins compared with 
oxytocin (Keirse & Van Oppen 1989b), but the use of prostaglandins is still associated with a 
2% to 5% failed induction rate (MacKenzie 1990).
The advantage of the use of local prostaglandins for labour induction is that the 
method is simple, non-invasive and convenient for both staff and patients. Expensive, technical 
equipment is not required for administration, the need for maternal and fetal monitoring while 
awaiting the establishment of labour is less, and patients can be freely ambulant, which they 
prefer (Williams et al 1980). Previously troublesome side effects such as nausea, vomiting, and 
tachycardias do not seem to be a feature with the local application of prostaglandins in doses
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necessary to achieve the desired clinical effects, although a minority of patients still experience 
minor side effects such as vaginal burning.
4.2 DISADVANTAGES
The onset of labour following vaginal administration of prostaglandins is not always 
predictable. Cervical ripening may take more than 12 hours (Walker & Gordon 1983) but 12% 
to 41% of women will go into labour during that time (Rayburn 1989). This may be 
detrimental in high risk pregnancies such as a previous uterine scar or where utero-placental 
insufficiency is suspected when the delivery suite may not have adequate resources to monitor 
the labour or to care for a distressed or immature infant. Others may require a second 
treatment before establishing labour while some respond by uterine hyperstimulation.
No widely accepted criteria exist for the definition of hyperstimulation. Nevertheless 
data from controlled trials suggest that the risk of hyperstimulation in prostaglandin treated 
women is 5.3% compared to 3.3% of controls (Keirse 1992). The incidence may vary in 
different centres according to their experience of the use of prostaglandins. Hyperstimulation 
can usually be effectively controlled by the administration of a tocolytic agent (Egarter et al 
1990), but none of the currently available prostaglandin formulations can be removed in the 
event of such an adverse reaction.
Uterine rupture of the unscarred uterus occasionally follows uterine hyperstimulation 
but is often associated with high risk factors. Only 9 cases in the third trimester of pregnancy 
have been reported in English (Maymon et al 1992).The dose of prostaglandin administered 
intravaginally in one case was 20mg (Claman et al 1984) while another report was concerned 
with uterine rupture in two grand multiparae (Larson et al 1984). Prostaglandins should be 
used with caution in such patients.
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Other aspects of the safety of prostaglandins include their effects on the fetus and 
neonate. Fetal distress is often observed both in spontaneous and induced labour, and there is 
no evidence from cord blood gas analyses that prostaglandin induced labour is any more 
hazardous than oxytocin induced or spontaneous labour (Thiery et ai 1978). Fetal death has 
occasionally been reported in association with prostaglandin use (Beazley & Gillespie 1971, 
Stewart & Calder 1981, Simmons & Savage 1984) but there is little evidence to cite 
prostaglandin as the direct cause unless associated with an adverse reaction such as uterine 
rupture (Larson ef a/ 1984)
Several authors have observed a reduced incidence of neonatal hyperbilirubinaemia in 
prostaglandin-induced labour compared to oxytocin-induced labour (Beazley & Weekes 1976, 
Chew 1977) but others have suggested that this difference is primarily associated with fetal 
maturity (Lange et al 1982). Other effects on the neonate are speculative. It is believed that 
PGE2 plays a role in maintaining the patency of the ductus arteriosus (Lucas & Mitchell 1978, 
Clyman et al 1980), but there is no evidence to suggest any effect of prostaglandins on the 
ductus in the dosages used in labour induction (Embrey 1983). Studies beyond the neonatal 
period have not revealed any untoward effects from labour induction with prostaglandins on 
children during the first five years of life (Friedman et al 1979, Van Pelt et al 1984, Boland et 
al 1990)
The administration of local prostaglandins for labour induction in women who have 
previously been delivered by Caesarean section has been shown to be both safe and effective 
(MacKenzie et al 1984, MacKenzie 1988). The incidence of scar damage in such patients 
appears similar to that occurring in spontaneous or oxytocin induced labour (Molloy et al 
1987, Phelan et al 1987, MacKenzie 1988, Taylor e/ al 1993). It has been suggested that 
prostaglandins may offer those women previously delivered by Caesarean section an enhanced 
probability of vaginal delivery (MacKenzie et al 1984, Taylor et al 1993).
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The major risks associated with the use of prostaglandins, namely the lack of 
predictability and hyperstimulation, may reflect the uncertain rate of release and absorption of 
PGE2 from different carrier vehicles in use. Many different dosage regimes and carrier 
vehicles have been used in an attempt to overcome these problems.
4.2.1 DOSAGE REGIMES
Many reports have been concerned with the optimum dosage of PGE2 required to 
maximise efficacy while minimising the risk of adverse effects. In the early studies where 
PGE2 was given either intravenously or orally, infusion rates or doses usually varied within 
the same trial highlighting the difficulty in judging an individual's response to prostaglandin. 
At present opinions differ on the optimum dosage regime both for cervical ripening and labour 
induction, and any given protocol may also be influenced by the carrier vehicle that is used 
(Mahmood 1989, Payne et al 1993, Murray et al 1995).
PGE2 has been applied vaginally in doses between Img and 5mg to achieve cervical 
ripening with little difference in outcome measures other than hyperstimulation. This risk was 
observed by some to increase with higher doses of PGE2 (Varma & Norman 1984,Graves et 
al 1985), but not by others (Smith et al 1996). Where PGE2 has been applied intracervically, a 
lower dose of PGE2 0.5mg has been used in most trials. Significant problems with fetal heart 
rate decelerations were reported in one study at this dose when compared with PGE2 0.25mg, 
although the onset of labour and its duration was significantly longer at the lower dose (Laube 
et al 1986). Higher intracervical doses have been used and associated with a reduced 
requirement for oxytocin augmentation but an increased the risk of uterine hyperstimulation 
(Mineratzis et al 1993).
Different dosage regimes have also been used for induction of labour with vaginal 
prostaglandins. It was reported in one study that the success rate of induction improved as the 
dose of PGE2 was increased from Img to 4mg but no difference was found between PGE2
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4mg and PGE2 5mg (Gordon-Wright & Elder 1979). However, as the authors pointed out, 
the latter doses were administered to different populations. There were no instances of 
gastrointestinal side effects or uterine hypertonus in the study. On the other hand a relatively 
high incidence of rapid labours was also reported in multigravidae using PGE2 5mg 
(MacKenzie & Embrey 1977) leading the authors to conclude that a lower dose of 2.5mg 
PGE2 was more appropriate in these cases. This was confirmed in a later study (Mackenzie et 
al 1981). Some cases of uterine hyperstimulation have been associated with risk factors such 
as grand multiparity (Shepherd et al 1981) and caution must be exercised in such cases.
Repeated administration of low-dose prostaglandin vaginally has been considered in 
some studies to improve safety while maintaining efficacy. It was demonstrated that repeated 
self-administration of pessaries containing either PGE2 0.2mg or 0.4mg to two unselected 
groups were effective and safe in labour induction (Liggins 1979). The mean total doses of 
PGE2 were similar in both groups (2.0mg and 2.3mg respectively) but labour was established 
in many more patients who received PGE2 0.4mg. A similar success rate to the repeated 
administration of PGE2 0.4mg was observed using PGE2 0.5mg (Hunter et al 1984) with a 
mean total dose of 2.8mg but when pessaries containing PGE2 3mg were assessed in this 
study, uterine hyperstimulation was experienced in two cases. More recently a comparison of 
intravaginal application of 2.5mg PGE2 given hourly or six hourly failed to reveal any 
differences in maternal or neonatal outcome(Carlan et àl 1995), although the incidence of 
hyperstimulation was found to be lower when using a 12 hourly regime of PGE2 2mg 
compared to a six hourly regime (Seeras et al 1995).
4.2.2 CARRIER VEHICLES
The instability of PGE2 created problems in the development of carrier vehicles for use 
in cervical ripening and labour induction. In the late 1970's formulations were produced by 
local hospital pharmacies as pessaries or viscous solutions. The pessaries were usually 
prepared by mixing an ethanolic PGE2 solution with either a witepsol or macrogol base while
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viscous solutions were prepared from tylose (hydroxy ethyl methyl cellulose) gel. The methods 
of preparation varied between pharmacies and the following 2 descriptions are taken from 
articles published in the Pharmaceutical Journal.
PREPARATION OF PROSTAGLANDIN E2 GEL Tarr M.J. & Tredree R.L. (1978)
Tylose is dispersed in distilled water at about 90°C to give a lump free suspension. 
This is then refrigerated overnight at 4°C, when a clear gel is produced. Aliquots of 10 g are 
filled into 1 oz Universal containers, capped and autoclaved at 121°C for 20 minutes. On 
autoclaving, the Tylose precipitates out, but it redissolves on cooling.
The required quantity of prostaglandin E2 is added under aseptic conditions, mixing 
being carried out with a sterile eye ointment spatula, and efficient distribution demonstrated by 
the addition of one drop of methylene blue injection. At ward level the gel is easily drawn up 
using a 20 ml syringe and sterile plastic quill.
PREPARATION OF PROSTAGLANDIN WITEPSOL PESSARIES London C. & Mills E. 
(1979)
Witepsol E75 is used as base, and is melted and allowed to cool as much as possible while 
remaining molten. Prostin E2 injection (10 mg/ml) is added and mixed thoroughly until all 
ethanol solvent has evaporated (this is detected by smell) and the pessaries poured. The 
Prostin E2 must, of course, be added at the lowest temperature compatible with evaporation of 
the alcohol. At present we give the pessaries a shelf life of seven days at 4°C, but experience 
suggests that the period may be extended in the future. However, until such time as we have 
more data available we only make the pessaries to order. The pessaries contain 2.5 mg 
prostaglandin E2 in a 1 g mould size.
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PGE2 is prepared by chemical synthesis as dinoprostone, which is an off-white 
crystalline solid with a melting point of 65°C solubility in water is l.Og/1 and it is freely soluble 
in methanol, ethanol and ethyl acetate. There are no known teratogenic or carcinogenic 
effects.
Cellulose gels (MacKenzie & Embrey 1978, Elder & Gordon-Wright 1979) witepsol 
based pessaries (Hefoi & Lewis 1980, Mackenzie et al 1981) and vaginal tablets (Kennedy et 
al 1982a) were all used with similar clinical success, but lacked long term stability. One of the 
problems was that of hydrolysis of PGE2 to PGA2 readily occurred in aqueous solutions, 
especially in the presence of acid or alkali. The shelf life was generally considered to be no 
more than 14 days when stored at 4°C, although in some pharmacies formulations were made 
up on a daily basis. The release rate of prostaglandin from these vehicles, as measured by 
changes in maternal plasma PGE metabolite levels was unpredictable, with wax based 
pessaries (MacKenzie et al 1987) associated with the most rapid rise in metabolite levels.
Commercially available PGE2 preparations have only recently become available as 
triacetin based gels or lactose based vaginal tablets. Gels containing 0.5mg PGE2 are available 
for endocervical administration while vaginal gels contain either Img or 2mg PGE2. Lactose 
based vaginal tablets contain 3mg PGE2. Apart from the intracervical gel, these preparations 
are all produced by the same pharmaceutical company, and have a shelf life of up to 24 months 
when stored at 4°C. Release of prostaglandin as measured by PGE metabolite levels is more 
rapid from the gel: in a study comparing the pharmacokinectics of prostaglandin release from 
the Img vaginal gel and 3mg vaginal tablet, the highest concentrations of PGE metabolite 
were achieved 20 minutes after administration of the gel. Peak levels following administration 
of the tablet occurred after 40 minutes and were less than 50% of those of the gel. Peak levels 
were maintained for 3 to 4 hours for both carrier vehicles but were more unpredictable with 
the gel (Greer et al 1990). Studies of metabolite levels following the use of the endocervical 
gel show similar results to those of the vaginal gel (Kimball et al 1986). '
56
There remains a need for greater predictability in cervical ripening and labour induction 
with the ultimate goal being the ability to stimulate cervical ripening without the onset of 
labour, which would have particular advantages in high risk pregnancies. Two new approaches 
require further investigation. It has already been shown that oral administration of a 
betamimetic prior to vaginal PGEg appears to inhibit prostaglandin induced uterine 
contractions (Goeschen et ai 1985) and the onset of labour (Insull et al 1990). The outcome 
of labour did not appear to be adversely influenced in either study. Strict intracervical 
application of PGE2 0.5mg in gel may have a similar effect (Granstrom et al 1990). This 
concept needs to be explored objectively. An alternative approach is a controlled release 
prostaglandin preparation and a unique controlled release non biodegradable cross-linked 
hydrogel polymer pessary has recently been developed and requires further evaluation.
4.3. THE CONTROLLED RELEASE CROSS-LINKED HYDROGEL 
POLYMER PROSTAGLANDIN PESSARY
4.3.1 INTRODUCTION
The PGE2 polymer pessary was designed by Graham of Strathclyde University 
(Graham et al 1980) and initial clinical trials were performed by Embrey working m 
corroboration with Graham (Embrey et al 1980). Each pessary is a flat, rectangular polymer 
slab with rounded ends measuring approximately 28.7mm long, 9.4mm wide, with a thickness 
which varies between 0.8mm and 1.1mm depending on the release characteristics required. 
The unloaded pessaries are prepared from three inactive constituents before PGE2 is loaded: 
polyethylene glycol 8000 (PEG 8000), 1,2,6, hexantriol (HT), and an isocyanate (Graham & 
McNeill 1984, McNeill & Graham 1984, Graham et al 1985). PEG is a partially crystalline 
solid or hydrogel consisting of chains of HO(CH2CH20)H, which is polymerised by the 
isocyanate, while cross-links between chains are formed by HT.
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4.3.2 MANUFACTURE
Manufacture of the polymer pessary was first developed by Graham and his colleagues 
in 1980 ( Graham et al 1980). The description that follows takes into account modifications to 
the procedure that were used to construct the pessanes that have been used for the clinical 
studies described in this thesis. The isocyanate used in the manufacture of the polymer pessary 
is Dicyclohexylmethane 4, 4-diisocyanate (DMDI).
The molecular weight of PEG 8000 is checked according to the United States 
Pharmacopeia XXI (1984), before it is dissolved at 85° C while being vacuum dried to remove 
any moisture. The solution is then sampled for moisture before addition of HT and DMDI in 
proportions where the molar ratio of PEG:HT:DMDI is 1:1.2:2 8. The reactants are stirred at 
500 R.P.M. for three minutes at 80 ± 3° C with ferric chloride as a catalyst to produce a bulk 
liquid polymer. This is cured at 95° C for three hours before being allowed to cool to room 
temperature. The polymer is sliced to the required dimensions before quality control testing 
for weight, thickness, crystallinity and swelling. Any unreacted PEG is removed in extractable
testing.
The polymer pessaries are loaded with PGE^ which is dissolved in a water/ethanol 
mixture at pH 4.0 so that PGE2 is totally non-ionised (pKa PGE2 = 4.9). Loading takes place 
by tumbling action after which the polymer pessaries are air-dried.
4.3.3 RELEASE CHARACTERISTICS
Release of PGE2 from the polymer pessary has been extensively studied in vitro for a 
range of polymer compositions (McNeill & Graham 1984, Embrey et al 1986) but there is 
little information on release characteristics in vivo. PGE2 release in vitro from an initially dry 
pessary is constant until approximately 50% PGE2 has been released after which release
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continues at a gradually decreasing rate. PGE^ release from a fully swollen pessary is 
proportional to the square root of time.
The mathematics of constant rates of drug delivery from simple swelling polymers 
were first studied in the early 1980s ( Peppas et al 1980, Lee 1980, Hopfenberg 1981). It was 
found that decreased resistance to drug difrusion occurred as the polymers became more 
swollen. Diffusion of prostaglandin from the hydrogel polymer in vitro however is more 
complex than this, and depends on a multitude of factors including the degree of crystallinity 
of the polymer matrix, the degree of cross-linking, the geometry of the device and the 
properties of the drug loaded into the device (McNeill & Graham 1984, Graham et al 1985). 
Drug release is governed by the degree of hydrogel swelling (McNeill & Graham 1984). These 
variables will be considered below.
The crystallinity of PEG is of paramount importance in terms of constant PGE2 
release. Constant release of a drug has never been achieved from a monolith which was not 
crystalline (Graham et al 1985). Once the pessary is rehydrated in a water bath, the crystallites 
dissolve and drug release can no longer remain constant but rapidly decreases with time. 
Crystallites therefore affect the pattern of release: the more crystallites that are present in the 
dry pessary, the longer the time taken for them to dissolve, and the slower the release rate. 
The crystallinity of PEG is increased by extending the chain length, which is achieved by the 
addition of DMDI.
The degree of cross-linking between chains of PEG depends on the amount of HT 
used in the preparation. Increasing the degree of cross-linking will prolong the period of 
constant drug release.
The geometry of the device affects drug release as thicker pessaries release the drug 
more slowly. Drug characteristics such as the amount of drug loaded into the pessary, the
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distribution of the drug within the polymer matrix and the solubility and diffusion coefficient of 
the drug in biological fluids all affect release rate.
Drug release is ultimately governed by hydrogel swelling which is thought to occur in 
three stages (McNeill & Graham 1984). When placed in saline, there is initial swelling of the 
polymer at the polymer-saline interface to form a gel layer, from which PGE2 diffuses along 
its concentration gradient according to Picks law where fractional release is proportional to 
the square root of time. As the hydrogel expands, the crystallites dissolve and resistance to 
diffusion decreases, so that drug release becomes approximately constant or zero order. Drug 
release remains constant as long as the hydrogel is expanding, even when the crystallites have 
all dissolved. This concept is poorly understood, but factors that may contribute include the 
presence of water in different forms, the diffusional path lengths, the surface area, the rate of 
dissolution of drug particles and drug concentrations in different regions of the hydrogel 
(Graham and McNeill 1985). Once fully swollen drug release again continues at a decreasing 
rate according to Picks Law.
4.3.4 TOXICOLOGY
PGE2 has been in clinical use for many years, while PEG has been approved by the 
F.D.A. for use in foodstuffs and pharmaceutical applications ( U.S. pharmacopeia XXI 1984). 
Similarly HT has been used in pharmaceutical applications (Martindale 1982).
Studies in the Bioengineering Department of Strathclyde University have not 
demonstrated any toxicity to mouse fibroblast cultures of the aliphatic isocyanate containing 
polymers either directly as made or after aqueous extraction (Gilchrist et al 1981). Further 
studies on rabbits and rats in vivo at the Huntingdon Research Centre failed to demonstrate 
any toxicity of the polymers (Huntingdon Research Centre Reports 1983).
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4.3.5 STABILITY
3H-PGE2 polymer pessaries have been stored for a year under refrigeration and their 
release profiles in vitro have not been shown to change (McNeill & Graham 1984). 
Furthermore the PGE2 content of clinical pessaries stored for a year at 4° C has not been 
shown to differ from the formulated content of the pessary, and studies at room temperature 
indicate pessary stability for at least six months (Embrey et al 1986).
4.3.6 CLINICAL TRIALS
The polymer pessary was first used clinically by Embrey and colleagues (Embrey et al
1980). Forty one primigravidae and 25 multigravidae with an unfavourable or favourable 
cervix were entered into the trial and treated with a polymer pessary usually about twelve 
hours before planned induction. The results are a little difficult to interpret as the dose of 
PGE2 incorporated into the pessary varied but most were treated with a pessary which 
released about 75% of its content over twelve hours, using a lOmg dose for primiparae and a 
5mg dose for multiparae. Effective ripening of the cervix was achieved in all primigravidae 
with an unripe cervix although no definition of effective ripening was given. Labour was 
initiated in 44% of these cases without the need for formal induction and in 70% primigravidae 
with a more favourable cervix. Two multiparae with an unfavourable cervix required formal 
induction but this need was obviated in 21 out of 23 multiparae with a more favourable cervix.
This trial was extended to include over 200 patients and reported in 1985 (Embrey & 
MacKenzie in 1985). Again the clinical benefits were shown to be similar to those obtained 
with pessaries in current use. A randomised trial comparing the polymer pessary with a 
witepsol pessary of PGE2 in 190 women undergoing labour induction with a moderately 
favourable cervix was later reported and a similar outcome of labour was observed for both 
pessaries (MacKenzie et al 1988). Neither of these trials concentrated on any outcome which 
might be improved by the use of controlled release prostaglandin. Some comment was made
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on the degree of pain experienced by patients during the ripening process in the first trial but 
no objective data given. No reference was made to the frequency and treatment of 
hyperstimulation during cervical ripening and labour induction.
Very little information is available on the release characteristics of the polymer pessary 
in vivo. In one study (Mackenzie et al 1987) the release and absorption profiles of PGE2 in 
different vehicles used for cervical ripening and labour induction including the polymer 
pessary were observed by measuring changes in plasma prostaglandin metabolite levels in 
patients being admitted for 2nd trimester therapeutic terminations. The results clearly 
demonstrated a slower rise and less variation in metabolite levels in association with the 
polymer pessary when compared to other formulations including wax pessaries, vaginal 
tablets, and cellulose gel.
4.4 AMS OF THESIS
The aim of this research was to ascertain whether prostaglandin delivery systems can be 
developed to provide greater predictability with an exclusively cervical effect so that cervical 
ripening can be uncoupled from the onset of labour. This would improve the safety profile of 
prostaglandins which would have particular advantages in high risk pregnancies. The trials in 
this thesis were designed to answer the following questions.
1 Is controlled release of PGE2 from the polymer pessary in vivo predictable as it is in
vitro?
2.1s controlled release of PGE2 from the polymer pessary associated exclusively with 
cervical ripening?
3.1s the use of oral tocolytics prior to vaginal PGE2 associated exclusively with 
cervical ripening?
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The following studies were undertaken.
SECTION 5. The pharmacokinectics of the polymer pessary were assessed in a phase 
II single centre open clinical study by a comparison of the in vivo and in vitro release profiles 
based on the hypothesis that there are no differences between in vivo and in vitro release 
profiles.
The theoretical advantages of the polymer pessary in labour induction are primarily 
based on its ability to deliver PGE2 at a controlled rate for absorption across the vaginal 
epithelium. Controlled release of PGE2 has been clearly demonstrated in vitro and depends on 
many factors including the molecular weight of PEG, pessary dimensions, the amount of 
PGE2 loaded into the pessary and the solubility of PGE2 (McNeill & Graham 1984). For any 
given pessary release rate is governed by hydrogel swelling. In vivo little is known of the 
pharmacokinectics of the polymer pessary and two observational studies using pessaries of 
different release profiles were therefore designed to compare in vivo and in vitro PGE2 release 
and to measure prostaglandin metabolite levels in vivo. The first study was conducted in 
nulliparae at term with a moderately favourable cervix and the second study in nulliparae and 
multiparae with an unfavourable cervix. In this way factors other than hydrogel swelling which 
might influence PGE2 release in vivo including parity, age, gestational age and Bishop score 
at entry into the trial could be analysed using multiple linear regression. Cervical ripening, 
outcome of labour and the condition of the neonate at birth were also assessed.
SECTION 6. The safety and efficacy of the polymer pessary was assessed in cervical 
ripening based on the hypothesis that a predictable slow release profile of PGE2 in vivo is 
associated exclusively with cervical ripening. This was a single centre, open, partially 
randomised phase H clinical trial in nulliparae at term with treatment success defined as any 
increase in Bishop score but failure to establish labour. Those women who satisfied these 
criteria were randomly allocated to receive either a second polymer pessary or intravenous 
infusion of oxytocin. The relative success of the second induction phase was assessed by
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comparing the time to delivery, mode of delivery, analgesic requirements and neonatal 
outcome. A sample size of 66 women in the second induction phase was proposed for a 90% 
power of detecting an 8 hour difference in the mean prostaglandin to delivery interval at the 
5% level.
SECTION 7. Oral administration of 8mg of salbutamol 30 minutes before vaginal 2mg 
PGE2 gel was assessed in a double blind placebo controlled trial based on the hypothesis that 
tocolytics suppress prostaglandin induced myométrial contractility and the onset of labour 
while allowing cervical ripening to take place. The primary outcome measure was an increase 
in Bishop score of 2 or more but without the onset of labour. Secondary outcome measures 
were time to delivery, mode of delivery, analgesic requirements and neonatal outcome.
The studies in this thesis were designed as far as possible to comply with normal 
delivery suite protocol. When patients are admitted to the John Radcliffe delivery suite, a 
cervical assessment is made and followed by insertion of a prostaglandin pessary in cases 
where the cervix is unfavourable or moderately unfavourable. Four to 6 hours later the cervix 
is reassessed and an amniotomy performed if the cervix is 2 or more cms dilated. 
Augmentation of labour with oxytocin is commenced 1 hour later if labour is not established. 
By adopting this policy within the trials where practical, it was possible to observe some 
effects such as amniotomy on outcome.
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PATIENT CONSENT AND ETHICS COMMITTEE 
APPROVAL FOR STUDIES
Central Oxford research ethics committee approval was obtained before commencing 
any of the studies reported in this thesis. Patients were only entered into a trial with their 
consent. Which was obtained at least twelve hours before each trial started, and following a 
full explanation of the procedures involved. All patients received an information sheet (see 
appendix 2) and were at liberty to withdraw from the trial at any time.
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SECTION 5:1 : THE CONCURRENT IN VIVO AND IN  VITRO RELEASE 
OF PGE2 FROM A POLYMER PESSARY DESIGNED TO 
RELEASE PGE21.0MG/HR
5.1.1 METHODS
Twenty four primiparae booked for induction of labour because of hypertension or 
prolonged pregnancy, with a modified Bishop score according to Calder et al (1974b) of five 
to eight were entered into the study. All patients had a singleton pregnancy with a fetal 
cephalic presentation and were 38 or more weeks gestation: those with a history of previous 
Caesarean section, suspected compromised fetal health or a maternal history of asthma were 
excluded.
Each patient in the study was allocated three identical pessaries labelled A, B, and C. 
Each pessary had a dry thickness of 0.8mm, dry weight of 0.23g, contained PGE2 lOmg (% 
relative sd 3.2) and had been manufactured to provide a release rate of PGE2 1.0mg/hr. 
Pessary A was inserted into the posterior vaginal fornix and at the same time pessaries B and 
C were placed in individual water baths containing 100 ml normal saline at 37° C.
Patients were allocated to one of eight subgroups according to a predetermined code. 
For each subgroup, pessary A was removed from the vagina and replaced by pessary B 
following its removal from the water bath while pessary C was simultaneously removed from 
the water bath at one of the following predetermined times: 0.5,1, 1.5, 2, 3, 4, 6, and 8 hours.
Pessary B was removed from the vagina at the end of the eight hour observation 
period (or not inserted in the eight hour subgroup). An amniotomy was performed if the cervix 
had dilated to two cms or more during the observation period, and if intravenous oxytocin 
augmentation was given the vaginal pessary was removed before the infusion started.
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All pessaries removed from the water bath or vagina were wiped dry, weighed, and 
stored at -24° C for subsequent assay of the residual PGE2 contained in the pessary. A 25ml 
aliquot of normal saline from each water bath was also stored at -24° C for subsequent PGE2 
assay. All prostaglandin assays were determined by HPLC according to the method described 
by Barras et al (1988) (appendix 2).
Maternal pulse, blood pressure, temperature, fetal heart rate, and uterine activity were 
recorded at hourly intervals during the eight hour observation period, and once active labour 
was established routine care was provided by the delivery suite staff.
To determine total PGE2 release in vivo, the amount of PGE2 in the pessary removed 
from the vagina was measured and subtracted from the total PGE2 incorporated in the 
pessary. The amount of PGE2 release in vitro was determined by assay of PGE2 
concentrations in the saline in which the pessary was immersed.
'5.1.2 RESULTS
Twenty four patients were studied with a mean ± sd age of 25 ± 4.3 years and a mean 
± sd gestation of 40.6 ±1.2 weeks.
The PGE2 release data for pessaries A and C are shown in table 1 and the weights of 
these pessaries following removal from in vitro or in vivo conditions are shown in table 2.
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TABLE !: PESSARY RELEASE DATA FOR INDIVIDUAL PATIENTS
PATIENT TIME 
IN VIVO
<h) i
TIME 
IN VITRO
m :
PGM
PESSARY
(mg) ;
PGIN
SALINE
(mg)
T O T # # #
RECOVERED releasedwmmmm
1. A 4.0 7.74 7.74 226
C 4.0 451 5.06 957 -
2 A 2.0 8.87 8.87 1.13
C 2.0 7.04 3.06 10.10 -
3 A 6.0 1.62 1.62 838
C 6.0 324 6.98 1022 -
4 A 1.0 921 921 0.79
C 1.0 7.83 zoo 9.83 -
5 A 15 8.91 8.91 1.09
C 15 7.40 3.43 10.83 -
6 A E
C - 85 2.84 637 921 -
7 A 05 9.04 9.04 0.96
C 05 9.08 0.82 9.90 -
8 A 3.0 834 834 1.66
C 3.0 5.60 3.86 9.46 -
9 A 3.0 8.07 8.07 1.93
C 3.0 632 3.76 10.08 -
10 A 05 9.86 9.86 0.14
C 05 8.78 0.92 9.70 -
11 A 4.0 5.87 5.87 4.13
C 4.0 5.09 4.76 9.85 - .
12 A 55 0.41 0.41 959
C 6.0 3.85 5.92 9.77 -
E = spontaneously expelled at deliveiy
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TABLE 1: PESSARY RELEASE DATA FOR INDIVIDUAL PATIENTS (continued)
PATIENT PESSARY TIME TIME PGIN PGIN T##EG %
IN VIVO IN VITRO PESSARY SALINE E E # m g B v^RELEASE'D::
m i (b) (mg) : S # # 3 S
13 A 4.7 4.98 4.98 5.02
C 8.0 3.06 7.49 1055 -
14 A 1.5 8.76 8.76 124
C 15 733 227 9.60 -
15 A 2.0 7.63 7.63 237
C 2.0 6.48 324 9.72 -
16 A 1.0 958 9.58 0.42
C 1.0 8.02 1.69 9.71 -
17 A 6.0 6.02 6.02 3.98
C - 6.0 3.71 4.80 8.51 -
18 A 4.0 9.39 939 0.61
C 4.0 5.36 428 9.64 -
19 A 8.0 0.69 0.69 931
C - 8.0 336 6.16 952
20 A 3.0 836 836 1.64
C 3.0 6.27 4.15 10.42 -
21 A 2.0 8.89 8.89 1.11
C 2.0 629 2.88 9.17 -
22 A 1.0 9.08 9.08 0.92
C 1.0 7.95 0.85 8.80 -
23 A 0.5 9.74 9.47 053
C 05 851 052 9.03 -
24 A 1.5 9.19 9.19 0.81
C 15 7.38 133 8.71 -
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TABLE 2: WEIGHT OF PESSARIES FOLLOWING REMOVAL FROM
IN VIVO OR IN VITRO CONDITIONS
PATIENT Tum m m illre iG H T  .
■ S S o v u -
1 A 4.0 0.73
C 4.0 0.83
2 A ZO 0.63
C 2.0 0.87
3 A 6.0 0.80
C 6.0 0.85
4 A 1..0 055
C 1.0 0.78
5 A 15 Q.63
C 1.5 0.83
6 A E •
C 8.5 0.80
7 A 05 0.64
C 05 0.75
8 A 3.0 Q.61 .
C 3.0 0.80
9, A 3.0 0.77
C 3.0 0.85
10 A 05 057
C 05 0.76
11 A 4.0 0.76
C 4.0 0.83
12 A 55 0.82
C 6.0 0.82
E = spontaneously expelled at delivery
Dry weight of pessary 0.23 g
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TABLE 2: WEIGHT OF PESSARIES FOLLOWING REMOVAL FROM
IN VIVO OR IN VITRO CONDITIONS (continued)
PATIENT TIME 
IN VIVO m
ojs4.7 8.0
15
15
ZO
ZO
1.0
1.0
6.0
6.0
4.0
4.0
0.77
Q.84
8.0
8.0
3.0
3.0
0.60
0.86
Z0
Z0
1.0
1.0
078
05
05
0.58
0.84
15
Dry weight of pessary 023 g
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Patient 6 sustained post-partum haemorrhage immediately after delivery and as a 
result, pessary A was lost to analysis. Pessary C was removed after the allocated time in this 
case. Pessary A was also removed from patients 12 and 13 before the allocated time because 
oxytocin augmentation was required while pessary C was removed from the water bath at the 
allocated time in these cases. Consequently three in vivolin vitro comparisons are not 
available.
PGE2 release m vivo and in vitro from pessaries A and C is illustrated in figure 5. 
Release from pessary A was slower during the first four hours compared to the subsequent 
observation period during which the rate of release increased with time. 50% of PGE2 was 
released by approximately five hours. PGE2 release from pessary C gradually decreased 
throughout the observation period with almost 50% released by five hours which was 
consistent with the pessary half life.
The relationship between PGE2 release and time was analysed using polynomial 
regression. In vivo a linear relationship was statistically significant with R squared = 0.7442, t 
= 7.817, and p< 0.001. A linear and quadratic relationship was also significant with R squared 
= 0.778 but neither the linear or quadratic terms were significant. A quadratic fit alone was 
best with R squared = 0.774, t = 8.48, and p< 0.0001. The regression equation was Y = 0.656 
+ 0.157 (x) squared as illustrated in figure 5.
In vitro a linear fit alone was also significant with R squared = 0.868, t = 12.028 and p 
< 0.0001.Regression with linear and quadratic terms was slightly better with R squared = 
0.926 and both terms significant (t = 7.89, p<0.0001 and t =. -4.054, p < 0.001 respectively). 
The regression equation was y = 0.15006 + 1.5226x - 9.0013e - 2x squared. The quadratic fit 
alone was less good (R squared = 0.711, t = 7.365).
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Figure 5 The in vivo and in vitro PGE2 
release from the polymer pessary 
during the observation period
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Other factors contributing to PGE2 release were analysed using multiple linear 
regression. In vivo PGE2 release was found to be independently related to hydrogel swelling 
as measured by % weight increase during the observation period.(F = 46.1, df 2,20 p < 
0.0001). Once the effect of the square of time had been factored out, the function of weight 
that best explained release was weight squared (t = 2.311, p < 0.03 for weight change squared 
and t = 4.6, p = 0.002 for time squared). PGE2 release was not related to Bishop score prior 
to treatment (t = -0.113, p = 0.911) or to patients age or gestation of pregnancy. In vitro 
hydrogel swelling was not independently related to PGE2 release.
Percentage weight increase of the polymer pessary in vivo and in vitro during the 
observation period is illustrated in figure 6. In vitro maximum swelling greater than 250% of 
pessary dry weight was reached in two hours after which no further weight increase occurred. 
In vivo there was a more gradual weight increase with maximum increase occurring towards 
the end of the observation period. Weight increase was significantly greater in vitro than in 
vivo (p<0.001 Wilcoxon signed rank test).
The calculated hourly release rate of PGE^ from pessary A in vivo and pessary C in 
vitro is shown in figure 7. The range of release in vivo varied from 0.15mg/hr to 1.92mg/hr 
and release rate was independent of time (N.S. T test). In vitro there was a gradual decrease in 
release rate during the observation period with R squared = 0.415 (p<0.001 T test).
Data of residual PGE^ contained in the polymer pessary for 21 patients where the 
pessary was removed from in vivo or in vitro conditions after identical release periods is 
shown in table 3. There was more PGE^ retained in the pessaries in vivo compared to in vitro 
(p= 0.01 Wilcoxon signed rank test) with only three cases where residual PGE^ in vitro 
exceeded that in vivo.
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Figure 7 The calculated hourly release of 
PGE2 from the polymer pessary during 
the observation period
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TABLE 3: RESIDUAL PGEz CONTENT OF PESSARIES REMOVED
FROM IN VIVO OR IN VITRO CONDITIONS
TIME
<h)
RESIDUAL PGË2 IN PESSARY A 
FOLLOWING IN W O  
CONDITIONS 
(ms)
RESIDUAL PGEz IN PESSARY C 
FOLLOWING IN VITRO 
CONDITIONS 
(mg)
05 9.04 9.08
05 9.86 8.78
05 9.74 851
1.0 9.21 7.83
1.0 958 8.02
1.0 9.08 7.95
15 8.91 7.40
15 8.76 733
1.5 9.19 738
2.0 8.87 7.04
2.0 7.63 6.48
2.0 8.89 639
3.0 834 5.60
3.0 8.07 632
3.0 836 637
4.0 7.74 451
4.0 5.87 5.09
4.0 9.39 536
6.0 1.62 334
6.0 6.02 3.71
8.0 0.69 336
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Pessary B was used to continue the ripening process in 18 patients. It was not inserted 
in two cases where oxytocin augmentation was required and in a further case where labour 
was already progressing satisfactorily at the time of pessary exchange. Pessary B was 
spontaneously expelled from the posterior vaginal fornix at an unknown time in six cases 
following amniotomy. The release characteristics of pessary B in vivo and time of amniotomy 
for 12 patients where the pessary was not spontaneously expelled are shown in table 4. In all 
cases the pessary was removed before the end of the observation period, either at delivery or 
prior to oxytocin augmentation. Using this data, it was possible to observe the effects of 
amniotomy on prostaglandin release: the calculated hourly release rate of PGE2 was 
significantly greater for 5 patients in whom an amniotomy was performed prior to the vaginal 
insertion of pessary B compared to seven patients in whom the procedure was performed 
following its insertion (p<0.05 Mann Whitney U test).
There were no differences in weight increase between C pessaries removed from in 
vitro conditions and B pessaries following both in vitro and in vivo conditions (N.S. Mann 
Whitney U test).
Twenty two patients in the study delivered vaginally with two patients requiring 
Caesarean sections, one for failure to progress and one following a failed forceps delivery. 
There were no cases of hyperstimulation and the total release of prostaglandin in vivo did not 
correlate with length of labour. Three patients sustained a post-partum haemorrhage of 
1000mls,1000mls and 1600mls respectively and two of these patients required blood 
transfusions. One neonate was bom with a five minute apgar score of 4 but the ten minute 
apgar score was 10. All other neonates were bom with five minute apgar scores of 8 or more 
and all were well at discharge from hospital.
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TABLE 4: RELEASE CHARACTERISTICS OF PESSARY B IN VIVO
FATTEST TIME 
IN VIVO 
00
TIME 
IN VITRO 
<b)
AMNIOTOMY
TIME
00
WEIGHT* AT 
REMOVAL 
(mg)
FGEjt
RELEASE
<mg)
2 45 2.0 3.9 0.85 553
3 1.8 6.0 5.6 0.78 3.05
4 3.3 1.0 43 0.84 1.67
7 45 05 2.8 0.82 7.94
8 21 3.0 53 0.81 1.99
9 1.1 3.0 3.1 0.80 3.74.
11 26 4.0 43 0.78 4.44
14 2.0 1.5 1.6 0.78 554
20 2.8 3.0 3.3 0.79 6.17
22 3.8 1.0 35 0.82 734
23 55 05 25 0.79 8.83
24 33 15 7.8 0.77 247
* = weight following removal from both in vitro and in vivo conditions
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SECTION 5.2: THE INFLUENCE OF A PARTIALLY SWOLLEN POLYMER PESSARY 
ON THE RELEASE OF PGE2 FROM A PESSARY DESIGNED TO RELEASE PGE2 
0.6MG/HR.
5.2.1 INTRODUCTION
The rate of hydrogel swelling of the polymer pessary governs controlled release of 
PGE2. Hydrogel swelling occurs more slowly in vivo which may explain why release of PGE2 
is initially slower and less predictable than in vitro. This might be overcome by pre-soaking 
the polymer pessary in normal saline prior to vaginal insertion.
This study was designed to compare in vivo release characteristics of a partially 
swollen polymer pessary with in vitro release characteristics. A pessary with a slower release 
profile than the pessary in section 6.1 was used in this study to allow comparison of different 
release profiles.
5.2.2 METHODS
Twelve multiparae and 13 primiparae booked for induction of labour because of 
hypertension or prolonged pregnancy with a modified Bishop score (Calder et al 1974b) of six 
or less were studied. All patients had a singleton pregnancy with a fetal cephalic presentation 
and were 38 or more weeks gestation: those with a history of previous Caesarean section, 
suspected compromised fetal health or a maternal history of asthma were excluded.
Each patient in the study was allocated three identical pessaries labelled A, B, and C. 
Two batches of pessary were used in the study: pessaries assayed at PGE2 9.9mg (% relative 
sd 1.3) were used in patients 1 to 7 inclusive while pessaries assayed at PGE2 10.9mg (% 
relative sd 3.5) were used in all other patients. Each pessary had a dry thickness of 1.1mm, dry 
weight of 0.32mg and was designed to provide a release rate of PGE2 0.6mg per hour.
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Pessary A was soaked for seven minutes in 25mls normal saline and inserted into the posterior 
vaginal fornix. A 10ml aliquot of the saline was frozen at -24 C for subsequent PGE2 assay. 
Methods were otherwise identical to those in section 5.1.2.
5.2.3 RESULTS
Patient details relating to age, gestation, and Bishop score before treatment are shown 
in table 5. There were no significant differences between the two groups (N.S Mann Whitney
U test).
The precise data of PGE2 release from pessaries A and C and the weights of these 
pessaries following removal from in vivo or in vitro conditions are shown in tables 6 and 7 
respectively. The results of weight gain for pessary A include any increases that occurred in 
the pre-soaking solution.
Pessary A was expelled at delivery from patient 16 and 20, and removed before the 
allocated time in patients 5, 9, 11 and 25 due to the requirement for oxytocin augmentation. In 
these cases pessary C was removed from the water bath at the allocated time and consequently 
six in vivolin vitro comparisons are not available. PGE2 release from pessary C in patient 16 
was not determined due to a faulty analysis and pessary C from patients 9 and 22 were lost 
during analysis. Aliquots of pre-soaking solution were lost to analysis in patients 1 to 4 
inclusive. Subjective technical difficulty was experienced in removing the pessaries from all
patients.
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TABLES: PATIENT DETAILS BEFORE TREATMENT
PRIMIPARAE MULTIPÀRAE
AGE(Yrs) 27.0 ± 3.2 26.9 ± 33
GESTATION (Wks) 40.7 ± 1.1 40.8 ±1.1
BISHOP SCORE 
BEFORE
TREATMENT 1 - 3 3 3
4 - 6 10 9
values are total patients or means ± sd
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TABLE 6: PESSARY RELEASE DATA FOR INDIVIDUAL PATIENTS
PATIENTPARITY PESSARY TIME TIME PGIN mm POM TOTAL PC wmamm
IN- IN PRE­ PES­ SALINE RECOVERED RELEASED
VIVO VITRO SOAK SARY mmtm
oo : Cb> (mg) (mg) (mg) (mg) # # # #
1 N A 0.5 N/A 9.97 9.97 0.00
C - 03 9.63 035 9.98 -
2 M A 1.0 N/A 9.74 9.74 0.16
C - 1.0 8.98 0.81 9.79 -
3 N A 4.0 N/A 8.46 8.46 1.44
C - 4.0 635 3.95 10.14
4 M A 1.5 N/A 9.51 931 039
C 13 831 1.32 9.63 -
5 N A 43 0.08 7.53 7.61 239
C - 6.0 5.72 4.92 10.64 -
6 N A 2.0 0.08 8.33 8.41 1.49
C 2.0 7.69 2.04 9.73 -  ; .
7 M A 3.0 0.08 8.46 8.54 136
C 3.0 630 234 9.04
8 N A 3.0 0.08 8.96 9.04 1.86
C 3.0 - 731 2.80 1031
9 M A 4.8 0.10 5.37 5.47 5.43
C - ■ 8.0 s 537 -
10 M A 0.5 0.10 10.23 10.33 037
C 0.5 9.25 0.61 9.86 -
11 N A 53 0.17 734 7.71 3.19
C - 6.0 - 6.09 433 10.62
12 M A 1.0 0.10 8.54 _ 8.62 238
C 1.0 8.95 1.0 10.05
Patients 1 -7 inclusive PGE2content assayed at 9.90mg 
Patients 8-25 inclusive- PGE2 content assayed at 10.90 mg 
* = faulty analysis 
N/A = not available
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TABLE 6: PESSARY RELEASE DATA FOR INDIVIDUAL PATIENTS (continued)
PATIENT PARITY PESSARY TIME
IN
VIVO
(b)
TIME 
IN 
VITRO 
(h) ;
PGIN
PR&
SOAK
(mg)
PGIN
PES­
SARY
<mg> ;
l i f i i
S ÏÜ I■ RËjÜEASÊDi i i i i l
13 M Ac 15 15 0.09 8.48823 1.69 8579.92
Z 33
14 M ê 2.0 zo 0.12 s 211 9.421020
1.48
15 N A
C
2.0
2*0
0.12 8.87
8.00 1.89
8.99
9.89
1.91
16 M A
C
6.8
8*0
0.12 Z82
4.90 *
2.94 7.96
17 N ê 4.0 4*0 0.08 5.486.13 4.88 55611.01
534
18 M A
C
0J
05
0.12 tÆ 0.67 iitl! 0.71
19 N A
C
4.0
4*0
0.13 m 325 1032 1.71
20 M ê 45 6*0 0.17 lit 433 10334 637
21 N AC
1.0
1*0
0.14 3J8 1.16 9.641036 126
22 N ê 15 15 0.12 9.45 1.77 957
133
23 N ê 2.0 2.0 0.08 8.578.75 139 225
24 N ê 3.0 3.0 0.10 u 3.01 i9a 6 1
153
25 M A
C
5.5
8*0
0.09 IS 526 1055 5.08
Patients 1 -7  inclusive PGEz content assayed at 9.90 mg 
Patients 8-25 inclusive- PGEz content assayed at 10.90 mg
* = faulty analysis
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TABLE 7: WEIGHT OF PESSARIES FOLLOWING REMOVAL FROM
IN VIVO OR IN VITRO CONDITIONS
PATIENT PARITY PESSARY TTME^S ^:^ T1MEh:^ ^WEIGHT^S
IN NTVDvxh # S i & m m m v m
1 N A 05 0.86c 05 0.93
2 M A 1.0 0.90
C 1.0 1.10
3 N A 4.0 1.11
C 4.0 121
4 M A 15 0.82
C 15 1.09
5 N A 43 1.06
C 6.0 1.15
6 N A 2.0 0.76
C 2.0 1.15
7 M A 3.0 0.90
C 3.0 1.13
8 N A 3.0 0.92
C 3.0 1.16
9 M A 4.8 0.97
C 8.0 1.13
10 M A 05 0.70
C 05 0.92
11 N A 53 1.03
C 6.0 1.11
12 M A 1.0 0.93
C 1.0 1.07
Dry weight of pessary = 032 g
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TABLET: WEIGHT OF PESSARIES FOLLOWING REMOVAL FROM
IN VIVO OR IN VITRO CONDITIONS (continued)
patient PARITY PESSARY TIME 
IN VIVO
W
TIME 
1N VITRO 
(h)
AT REM OVAL : :
13 M ê 13 13 !$
14 M ê 2.0 2*0
15 N ê 2.0 2?0 t î î
16 M ê 6.8 s'o 1:11
17 N ê 4.0 4j0 1.071.10
18 M AC
03
03
0.64
0.91
19 N AC
4.0 4*0
0.95
,1.19
20 M AC
43
6*0
0.95
1.13
21 N ê 1.0 L0 0.831.09
22 N A
C
13
13
0.77
1.13
23 N A
C
2.0
2*0
1.05
1.15
24 N A
C
3.0
3*0
0.90
1.15
25 M A
C
53
8*0
1.07
1.15
Dry weight of pessary = 032 g
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The calculated mean release of PGE2 from the pessary into saline during pre-soaking 
was 0.1 mg with a range of 0.08 to 0.17mg.
PGE2 release in vivo and in vitro from pessaries A and C is illustrated in figure 8. 
Polynomial regression indicated that a quadratic fit was best in vivo (R squared =0.703, t = 
7.375, p < 0.0001) with a regression equation of Y = 0.826 + 0.145 (X) squared. In vitro the 
linear and quadratic fit was best (R squared = 0.956, t = 9.69, p < 0.0001) with a regression 
equation of y = -0.14380 + 1.2298x - 6.8604e - 2x squared.
Multiple linear regression indicated that hydrogel swelling was not independently 
related to PGE2 release in vivo or in vitro, and that there were no differences in PGE2 release 
rates between primiparae and multiparae.
Fluid uptake by the polymer pessary measured as percentage weight increase during 
the observation period is illustrated in figure 9. The results in vivo included any increase that 
may have occurred during the pre-soaking period. Percentage weight increase was 
significantly greater in vitro than in vivo (p < 0.001 Wilcoxon signed rank test).
Table 8 compares the residual PGE2 content of the polymer pessary in vivo (including 
any loss into the pre-soaking solution) and in vitro in those cases where the pessary was 
removed after identical release periods. There was significantly more residual PGE2 contained 
within pessaries used in vivo (p< 0.05 Wilcoxon signed rank test) with only three cases where 
residual PGE2 in vitro exceeded that in vivo.
PGE2 release data for pessary B and the time of amniotomy for 15 patients where the 
pessary was used to continue the ripening process are shown in table 9. Pessary B was not 
inserted in five cases where oxytocin augmentation was required, and it was spontaneously 
expelled from the posterior vaginal fornix in a further two cases.
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Figure 8 The in vivo and in vitro PGE2 
release from the polymer pessary 
during the observation period
°  In vivo
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Figure 9 Fluid uptake by the polymer 
pessary as measured by 
% weight Increase
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TABLES: RESIDUAL PGEz CONTENT OF PESSARIES REMOVED
FROM IN VIVO OR IN VITRO CONDITIONS
ÏÎMÉ
<h>
lŒ Sm tîA L toB ïN  ÈëSSàRYà  
FQlJLÔWÏNOfôfVIVO 
CONDITIONS 
Ong)
0.5 9.97 9.63
05 10.23 925
0.5 10.07 9.45
1.0 9.74 8.98
1.0 8.52 8.95
1.0 9.50 9.20
1.5 9.51 831
1.5 8.48 8.23
2.0 8.33 7.69
2.0 930 8.09
2.0 8.87 8.00
2.0 837 8.75
3.0 8.46 630
3.0 8.96 731
3.0 9.27 7.60
4.0 8.46 6.55
4.0 5.48 6.13
4.0 9.06 7.07
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TABLE 9: RELEASE CHARACTERISTICS OF PESSARY B IN VIVO■ W ÊÈËm m■ B B S e mm
1 35 05 4.0 1.08 121
2 2.6 1.0 35 1.10 1.77
6 2.1 2.0 43 1.06 2.41
7 23 3.0 3.0 1.08 2.49
8 23 3.0 5.3 1.10 654
10 2.9 05 33 0.92 259
13 0.9 15 15 1.04 3.17
14 . 3.8 2.0 4.2 0.95 3.96
15 ' 2.2 2.0 2.0 1.05 2.18
18 4.7 05 3.8 1.09 3.89
19 05 4.0 4.0 1,11 2.61
21 5.0 1.0 4.0 1.00 539
22 4.7 15 33 1.12 6.05
23 23 2.0 1.8 1.04 7.19
24 23 3.0 4.0 1.11 1.16
* = weight following removal from both in vitro and in vivo conditions
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There were no differences in PGE2 release rate for patients in whom an amniotomy 
was performed prior to the vaginal insertion of pessary B compared to those in whom the 
procedure was performed following insertion (N.S. Mann Whitney U test). However PGE2 
release was greater than predicted in patients 8,13,19 and 23, with calculated hourly release 
rates of 2.8mg,3.5mg,5.2mg and 3.1mg respectively. An amniotomy had been performed prior 
to pessary B insertion in patients 13, 19 and 23. There were no significant differences in 
weight increase between C pessaries removed from in vitro conditions and B pessaries 
following in vitro and in vivo conditions (N.S. Mann Whitney U test).
The calculated hourly release rates of PGE2 from the polymer pessaries used in vivo in 
sections 5.1 and 5.2 are compared in figure 10. There were no significant differences in hourly 
release rates during the observation period between the pessaries of different release profiles 
(N.S. Mann Whitney U test).
Figure 11 compares percentage weight increase of the polymer pessaries used in vivo 
in section 5.1 and those used in vivo in section 5.2, including any increases that occurred 
during the pre-soaking period. There were no significant differences in weight increase 
between the pessaries during the observation period (N.S. Mann Whitney U test).
The outcome of labour was similar for both parity groups. Eleven primiparae delivered 
vaginally while two required a Caesarean section for cephalopelvic disproportion. All 
multiparae delivered spontaneously. The length of labour did not correlate with the total 
amount of prostaglandin administered in vivo, and there were no cases of hyperstimulation in 
either parity group. However pessary B was removed from a primiparous patient (19) when 
she experienced only short intervals between painful contractions from 4 to 4.5 hours after 
pessary insertion. There was no fetal distress, contractions diminished, and the patient 
subsequently required oxytocin augmentation. PGE2 1.71mg was released from pessary A 
inserted vaginally for 4 hours in this patient and PGE2 2.61mg was released from pessary B 
inserted vaginally for 0.5 hours.
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One neonate was bom with apgars of 2 at one minute and 3 at five minutes, thick 
meconium having been noted at birth. The 10 minute apgar was 10 and the neonatal outcome 
good. One neonate bom by Caesarean section with apgars of 6 at one minute and 9 at five 
minutes was admitted with seizures at 18 hours to the special care baby unit. No cause for the 
seizures was identified and the baby was discharged on long term anticonvulsants.
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SECTION 5.3: PERIPHERAL PLASMA PROSTAGLANDIN METABOLITE 
LEVELS DURING CERVICAL RIPENING WITH THE POLYMER PESSARY 
AND CLINICAL SIGNIFICANCE RELEVANT TO SUBSEQUENT LABOUR
5.3.1 INTRODUCTION
Prostaglandin metabolite levels have often been used to assess the release 
characteristics of various vaginal PGE^ preparations used in the induction of labour 
(Gordon-Wright & Elder 1979, Kimball et al 1986, MacKenzie et al 1987) and observe the 
absorption rate of PGE^ across the vaginal epithelium. This study was designed to compare 
in vivo release of PGE^ from the polymer pessary with changes in peripheral plasma 
prostaglandin metabolites and to correlate the changes in metabolites with clinical responses 
obtained.
5.3.2 METHODS
Twenty four patients investigated in section 5.1 and 25 patients investigated in section
5.2 were recruited for this study. Blood samples were collected into 10ml plastic tubes 
containing 100 microlitres of lOOmM acetyl salicylic acid, pH 7, and 1ml of 3.8% sodium 
citrate, pH 7.4, prior to initial pessary insertion and at intervals of 0.5, 1, 2, 4, and 8 hours 
where delivery had not occurred. The samples were centrifuged at 4°C for five minutes at 
25Q0g and the plasma layer separated and stored at -70°C until assayed.
For each plasma sample collected and stored, the principal circulating FGF^ 
metabolite 13,14, dihydro-15-heto-FGF^ (PGFM) was measured as its methyloxime 
derivative (Kelly et al 1986), while the bicyclo prostaglandin E metabolite (PGEM) was 
measured according to the method described by Demers et al (1983).
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PGFM ASSAY
Sample preparation
Samples collected were prepared by pipetting 500pl of plasma, 500pl of 25% ethanol 
solution and lOjil of acetic acid into 1.5ml tapered polypropylene microfiige tubes. These 
were then gently mixed and left at room temperature for five minutes before being spun at 
12,000g for two minutes. The supematent was applied to conditioned Bond-Elut columns 
and washed with 3mls of distilled water followed by 3mls hexane. Prostaglandin was eluted 
from the columns into glass tubes with two 750pl aliquots of ethyl acetate, which was then 
removed under a stream of nitrogen. The prostaglandin samples were reconstituted with 
150pl of methyloximating solution and 350pl of assay buffer (see page 101), mixed 
thoroughly by vortex agitation and left overnight at room temperature.
Standard preparation
106.32pg of 13,14-dihydro-l 5-oxo-Prostaglandin (supplied by Cayman chemicals, 
Ann Arbor,Michigan,U.S.A.) were dissolved in 500pl methyloximating solution, left at room 
temperature overnight, and made up to 5mls with ethanol. Using siliconised glassware to 
avoid possible adsorption of prostaglandin onto glass, 100 pi of this solution was diluted with 
0.01% triton-100 in phosphate buffer gelatine saline to obtain 10 standard concentrations 
ranging from 1.06pg to 531.6pg per tube.
Assay procedure
In duplicate, lOOpl of each standard and sample were pipetted into separate 
polypropylene tubes. 100pi of Iodine 125 PGFM methyloxime radiolabel solution and lOOpl 
of rabbit anti PGFM methyloxime (both supplied by Dr. R.W. Kelly, M.R.C. centre for
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Reproductive Biology, Edinburgh) were added to each tube except those for non specific 
binding estimation. All tubes were agitated and left overnight at room temperature.
Separation of bound from free PGFM was achieved by the addition of 200pl of 
magnetic antibody preparation (available from Dr. R.W.Kelly) to all tubes except the total 
count tubes, followed by the application of a magnet. The supernatant was discarded and the 
pellet was washed in 300pl triton buffer and recentrifuged. The radioactivity of each sample 
was then counted using a gamma counter and a standard curve prepared by plotting the ratio 
of B/Bo versus the amount of prostaglandin metabolite added where
BHodinated PGFM bound at each standard concentration minus non specific binding
Bo=iodinated PGFM bound in the absence of unlabelled PGFM 
minus non specific binding
The quantity of PGFM in each sample was calculated from this curve.
A typical standard curve is illustrated in figure 12. The sensitivity of the assay was 
2pg and the 50% displacement value was 16pg. The intra-assay coefficient of variance was 
10.2% (n=10) and the inter-assay coefficient of variance was 13.2% (n=4).
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Figure 12 PGFM standard curve
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PGEM ASSAY
Sample preparation
500jil of each plasma sample was alkalinised to pH 11 by the addition of 30pl 1M 
NaOH and incubated at 25° C for 48 hours. The samples were then neutralised to pH 7.4 by 
addition of 70 pi KH2PO4 and 1% NaNg.
Standard preparation
The standards were prepared by addition of 20pl of a stock solution containing 
1 jig/ml of 11-16 bicyclic analogue of PGAM to 2mls of 4% Bovine Serum Albumin(BSA) in 
TG buffer. This working solution was further diluted with BSA in assay buffer to obtain 10 
standard concentrations. Otherwise PGEM standard solutions were alkalinised as described 
under sample preparation.
Bicyclo PGEM label preparation
25pCi PGEM was evaporated to dryness under nitrogen and then resuspended 
with 2.5 mis ethanol and stored at - 20° C. Conversion to Bicyclo PGEM was achieved by 
taking 1ml of stock, evaporating to dryness under nitrogen, and resuspending in 1.2 mis 
distilled water: This was alkalinised to pH 11 by addition of 50gl 0.25M NaOH and incubated 
at 37° C for 24 hours before acidifying to pH 3 with lOpl citric acid. Tritiated bicyclo PGEM 
was then extracted three times with 2.4mls ethyl acetate, evaporated to dryness under 
nitrogen, and stored in 1ml ethanol at -20° C.
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Assay procedure
In duplicate, lOOpl of each standard and sample were pipetted into separate 
radioimmunoassay tubes. lOOpl of PGEM label and lOOpl anti PGEM rabbit antiserum both 
diluted in assay buffer were added to each tube. Three other sets of tubes were prepared in 
duplicate: The total count tubes, non specific binding tubes (containing no antibody), and the 
zero standard tubes. All tubes were incubated overnight at 4° C. Bound and free bicyclo 
PGEM were separated by the addition of 1 ml of 10% (wt/volume) charcoal suspension in tris 
buffer (see below) and the tubes were incubated at 4° C for 14 minutes before being 
centrifuged at 4° C for 10 minutes at 2500g. The supernatant was added to 1 Omis scintillant in 
a vial and counted in a beta counter. A standard curve was prepared as described for PGFM 
and the amount of PGEM in each sample calculated.
A typical standard curve is illustrated in figure 13. The sensitivity of the assay was 2pg 
and the 50% displacement value was 45pg. The intra-assay coefficient of variance was 9.3% 
(n=10) and the inter-assay coefficient of variance was 12.1% (n=4).
1M Tris buffer (pH 7.4)
Trizma HC139.4g, H20 250ml. Adjust to pH 7.4 with Na OH.
Assay buffer
1M Tris buffer (pH 7.4) 10ml
EDTA 67.2mg
Naazide lOOmg
H20 190ml
Add Ig bovine y globulin. Stir on a mixer until dissolved.
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Figure 13 PGEM standard curve
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5.3.3 RESULTS
PGEM concentrations are tabulated in table 10 and PGFM in table 11 for 21 of the 24 
patients studied in section 5.1. Patients 13,16, and 19 declined blood letting following 
difficulty in obtaining venous access during the first hour and their results have been excluded 
from the analysis. Patients 2, 6, 7, 11 and 15 delivered within the eight hour observation 
period at which time the pessary was expelled and the eight hour sample not collected. Three 
other samples were not collected due to technical difficulties. Pessaries A or B were either 
spontaneously expelled or removed prior to oxytocin augmentation from all other patients 
between four and eight hours.
The median baseline PGEM concentration was 188 pg/ml with an interquartile range 
of 102 to 305 pg/ml while the median baseline PGFM level was 70 pg/ml with an interquartile 
range of 39 to 133 pg/ml. There was no relationship between baseline PGEM or PGFM levels 
and pre-treatment Bishop scores or gestation (N.S. Kruskal Wallis test).
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TABLE 10: PGEM CONCENTRATIONS FOR INDIVIDUAL PATIENTS IN
SECTION 5 .1
mmm .
7401620
2050
639
307
1700
1720
733
150
1250
1500
670
157
720
1000
688
129
410
900
360
150
468
211246352199142110
826527150220188
620858957273
216835242133125
201424440349238161
170777885628232133
820652812N/A133
130622478250144
251387208
3641150443237
460540370320330330
310350340325320320
N/A310265210220210
4052500240100197205
N/A790880555318188
325830220185510290
850820430250232223
D — delivered
N/A = not available
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TABLE 11: PGFM CONCENTRATIONS FOR INDIVIDUAL PATIENTS IN
SECTION 5 .1
S M w m m
1 64 166 166 178 225 130
2 112 114 114 190 360 D
3 38 92 72 107 100 81
4 10 60 53 46 24 89
5 41 35 138 158 1203 654
6 173 213 228 312 984 D
7 35 68 20 41 33 D
8 40 80 73 61 176 212
9 140 300 308 549 366 140
10 125 279 425 278 359 227
11 31 N/A 312 249 264 D
12 70 89 120 144 211 314
14 87 171 37 40 N/A 414
15 269 307 60 198 194 1 D
17 270 64 53 34 340 320
18 85 122 85 124 82 385
20 2 4 2 2 240 N/A
21 52 65 85 59 320 430
22 103 179 147 280 120 N/A
23 44 140 205 510 510 450
24 148 200 170 148 120 630
D = delivered 
N/A = not available
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The median and interquartile range of PGEM and PGFM change from baseline 
following pessary insertion is shown in figure 14. PGEM levels had risen significantly from 
baseline levels at two and four hours following pessary insertion (p<0.01 Friedman analysis of 
variance) but had returned to baseline levels at eight hours. PGFM levels had risen 
significantly two hours following pessary insertion and remained elevated for the subsequent 
observation period (p<0.01).
The maximum increase in PGEM levels was greater than 600 pg/ml for the five 
patients who delivered during the observation period (early labourers) compared to six out of 
16 patients who delivered after that time (late labourers) (p< 0.05 Fisher Exact test). The 
change in PGEM levels from baseline was also greater in early labourers two hours following 
pessary insertion although there were no significant differences between the two groups at any 
other time (N.S. Mann Whitney U test).
PGEM and PGFM concentrations are tabulated in tables 12 and 13 respectively for 
patients studied in section 5.2. Samples were not collected at four hours from patients 2, 13, 
and 20 and at eight hours from patients 2, 4, 6, 12, 13, 16, 17, and 20 who had delivered 
within that time. All other samples at eight hours were obtained following spontaneous 
pessary expulsion or removal prior to oxytocin augmentation between four and eight hours. A 
further five samples were not collected due to technical difficulties.
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Figure 14 Prostaglandin metabolite change 
from baseline concentrations during 
the observation period
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TABLE 12: PGEM CONCENTRATIONS TOR INDIVIDUAL PATIENTS IN
SECTION 5 .2
W S M B .
;XyXvH;!j0^5-iv^">lvB p s B
H
I g g
i N 220 560 510 405 590 290
2 M 275 220 260 440 D D
3 N 370 360 413 470 720 480
4 M 740 580 430 1280 1350 D
5 N 230 355 320 580 710 310
6 N 266 210 450 353 780 D
7 N 78 142 290 590 1120 N/A
8 M 235 113 76 163 78 475
9 M 290 280 445 325 480 415
10 M 205 100 332 580 560 320
11 N 245 143 150 195 320 562
12 M 170 1020 1660 1520 1200 D
13 M 226 1220 1800 1888 D b
14 z M 190 124 139 148 568 N/A
15 N 79 108 252 560 740 149
16 M 95 235 445 630 240 D
17 N 148 102 2180 2000 1670 D
18 M 108 305 242 205 236 164
19 N 108 231 550 690 770 375
20 M 142 360 665 1020 D D
21 N 240 N/A 240 620 280 600
22 N 97 210 134 160 275 N/A
23 N 165 635 630 1260 660 134
24 N 230 - 250 580 600 280 530
25 M 154 190 350 240 550 N/A
D = delivered
N/A = not available
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TABLE 13: PGFM CONCENTRATIONS FOR INDIVIDUAL PATIENTS IN
SECTION 5 .2
M Ë E w m m
I S l l l l l l [ill B t l l l l
###$:##: I S I t S i rap Ig iE
1 N 58 118 155 259 357 380
2 M 63 69 356 130 D D
3 N 91 129 201 118 123 394
4 M 73 133 50 120 850 D
5 N 23 53 60 93 62 174
6 N 90 80 166 371 51 D
7 N 34 14 26 47 131 N/A
8 M 10 14 28 10 171 338
9 M 12 56 39 130 121 338
10 M 20 71 61 99 115 196
U N 49 32 120 47 225 526
12 M 12 104 378 370 165 D
13 M 31 59 255 521 D D
14 M 30 447 66 54 166 N/A
15 N 96 106 22 200 425 417
16 M 10 10 10 48 43 D
17 N 69 138 952 858 340 D
18 M 92 84 21 63 167 471
19 N 78 88 74 213 111 152
20 M 70 81 131 266 D D
21 N 10 N/A 10 10 16 90
22 N 10 10 10 10 10 N/A
23 N 10 14 27 28 88 145
24 N 10 10 10 166 10 1100
25 M 16 10 10 35 31 N/A
D = delivered
N/A = not available
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The median baseline PGEM level was 205pg/ml with an interquartile range of 125 to 
243pg/ml while the median baseline PGFM level was 31 pg/ml with an interquartile range of 11 
to 72pg/ml. There were no significant differences in prostaglandin metabolite levels between 
multiparae and primiparae at any of the sampling times (N.S. Mann Whitney U test) and there 
was no relationship between metabolite levels and pre-treatment Bishop scores (N.S. Kruskal 
Wallis test). Baseline PGEM levels were significantly lower at 42 weeks gestation compared 
with earlier gestations (p< 0.05 Kruskal Wallis test) although there was no similar relationship
with PGFM levels.
Figure 15 illustrates the median and interquartile range of PGEM and PGFM change 
following pessary insertion. PGEM levels had risen significantly two hours following pessary 
insertion, remained elevated at four hours but returned to baseline at eight hours (p<0.01 
Friedman analysis of variance). PGFM levels had risen significantly four hours following 
pessary insertion (p<0.01) and remained elevated for the subsequent four hour observation 
period. Patient 19, whose labour was associated with excessive uterine activity sustained a 
maximum increase in PGEM levels of 662pg/ml.
Changes in plasma PGEM and PGFM concentrations during the first four hours for 
eight patients who delivered within the observation period (early labourers) and 17 patients 
who delivered later (late labourers) are illustrated in figure 16. PGEM levels had risen above 
baseline two hours following pessary insertion in both groups (p< 0.01 Friedman test) but 
changes were significantly higher in early labourers compared to late labourers at one, two, 
and four hours following pessary insertion (p<0.05 Mann Whitney U test). The maximum 
increase in PGEM levels was greater than 500pg/ml for seven out of eight of these women 
compared to four out of 17 late labourers (p< 0.01 Fisher Exact test). PGFM levels had risen 
above baseline by two hours in early labourers and four hours in late labourers (p<0.005 
Friedman test) and changes were higher in the former group at one and two hours following 
pessary insertion compared to the latter group (p<0.05 Mann Whitney U test). There were
no significant differences between the two groups at four hours.
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Figure 15 Prostaglandin metabolite change 
from baseline concentrations during 
the observation period for patients 
In section 5.2
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Figure 16 Prostaglandin metabolite change 
from baseline concentrations during the 
first four hours of the observation period
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Figure 17 illustrates the median and interquartile range of PGEM change from baseline 
during the observation period for patients treated with the polymer pessary designed to release 
PGE2 1.0mg/hr compared with those treated with the polymer pessary designed to release 
0.6mg/hr.
There were no differences in PGEM for the polymer pessaries of different release 
profiles at any of the sampling times (N.S. Mann Whitney U test). Changes in PGEM levels 
were significantly correlated with PGE^ release from pessary A in 11 and 13 patients studied 
in sections 5.1 and 5.2 respectively in whom metabolites were assayed at the time of pessary A 
removal (p<0.05 and p<0.01 Spearman's rank correlation) as shown in figure 18. A similar 
relationship was not observed for PGFM levels. There was also an inverse association between 
the maximum change in PGEM levels and pessary to delivery interval for 19 patients in section
5.1 (p<0.05 Spearman's rank correlation) and 23 patients in section 5.2 (p<0.05 Spearman's 
rank correlation) who delivered vaginally as shown in figure 19.
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Figure 17 Comparison of PGE2 metabolite 
change for polymer pessaries of 
different release profiles
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Figure 18 Changes in PGEM levels for 
known amounts of PGE2 release 
from the polymer pessary
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Figure 19 Maximum changes in PGEM levels 
observed during labour
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SECTION 5 4 CERVICAL RIPENING FOLLOWING ADMINISTRATION OF THE
POLYMER PESSARY AND ASSOCIATED CHANGES IN PROSTAGLANDIN
METABOLIC LEVELS
5.4.1 INTRODUCTION
Ripening of the cervix following local administration of prostaglandins is not always 
predictable with some patients failing to respond while others commence labour during the 
ripening process. This may be related to the variable release rate ofPGE^. This study was 
designed to correlate cervical changes during the ripening process with both release of PGE^ 
from the polymer pessary and associated changes in prostaglandin metabolite levels.
5.4.2 METHODS
Twenty four patients investigated in section 5.1 and 25 patients investigated in section
5.2 were recruited for this study. Cervical assessment was made immediately prior to pessary 
A insertion into the posterior vaginal fornix and at the time of pessary A removal in all patients 
using a modified Bishop scoring system according to Calder ei al (1974). The clinical study 
was otherwise as described in sections 5.1 and 5.2. All results were analysed by Spearman's 
rank correlation.
5.4.3 RESULTS
Cervical score data is tabulated in tables 14 and 15 for patients in section 5.1 and 5.2 
respectively.
There was no relationship between PGE2 release from pessary A and cervical score 
increase for all patients in section 5.1 and primiparae in section 5.2.
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TABLE 14: CERVICAL SCORE DATA FOR INDIVIDUAL PATIENTS IN
SECTION 3 .1
* — R E l^ E k oM
1 5. 9 4 226
2 6 8 2 1.13
3 7 9 2 838
4 5 6 1 0.79
5 6 7 1 1.09
6 8 13 5 N/A
7 5 5 0 0.96
8 5 6 1 1.66
9 5 7 2 1.93
10 7 8 1 0.14
11 7 10 3 4.13
12 6 10 4 939
13 7 9 2 5.02
14 8 8 0 124
15 7 10 3 237
16 6 6 0 0.42
17 7 8 1 3.98
18 6 9 3 0.61
19 7 10 3 931
20 8 9 1 1.64
21 5 5 0 1.11
22 5 5 0 0.92
23 7 7 0 0.53
24 6 6 0 0.81
N/A = not available
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TABLE 15: CERVICAL SCORE DATA FOR INDIVIDUAL PATIENTS IN
SECTION 5 .2
M I S ! W Ê Ê Ê S
WÊëmMMËm
m m m m m
W Ê S Ê IË Ë
■ E S m b b
m m fàfflm am
9B È Ë Ê U Ê È
:;cE nge;in::
— i
I S iS B S S
S m m m m
W Ê Ê Ê Ê Ë
i N 4 7 3 0
2 M 6 8 2 0.16
3 N 4 6 2 1.44
4 M 5 7 2 039
5 N 6 6 0 2.29
6 N 6 6 0 1.49
7 N 1 2 1 136
8 M 5 6 1 1.86
9 M 5 7 2 5.43
10 M 5 5 0 037
11 N 5 10 5 3.19
12 M 5 11 6 238
13 M 6 11 5 233
14 M 1 5 4 1.48
15 N 6 6 0 1.91
16 M 6 13 7 7.96
17 N 5 10 5 534
18 M 3 4 1 0.71
19 N 4 9 5 1.71
20 M 6 13 7 637
21 N 5 5 0 136
22 N 6 6 0 133
23 N 6 7 1 2.25
24 N 5 5 0 133
25 M 4 5 1 5.08
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A significant association for multiparae in section 5.2 was observed (p< 0.05) but six 
of these women established labour during the observation period.
There was no association between cervical score increase and the corresponding 
changes in PGEM and PGFM where these were measured at the same time for women m
either section.
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SECTION 6 THE SAFETY AND EFFICACYOF THE POLYMER PESSARY 
IN CERVICAL RIPENING AND EXTENDED INDUCTION
6.1 INTRODUCTION
Many carrier vehicles have been used in an attempt to find a formulation with uniform 
drug release including wax pessaries, tablets and cellulose gels, but their release profiles have 
been shown to be erratic (MacKenzie et al 1987). The observations from section 5 suggest 
that these qualities are associated with the use of the polymer pessary. Controlled release of 
prostaglandin may allow cervical ripening to take place without the onset of labour which 
would have particular advantages in high risk pregnancies. The objective of this study was to 
evaluate the efficacy and safety of the polymer pessary in achieving cervical ripening in 
nulliparae at term with an unfavourable or partially favourable cervix. At the end of a 12 hour 
treatment period , those women who had failed to respond adequately were randomised to 
receive induction either with a second polymer pessary or by intravenous infusion of oxytocin.
6.2 METHODS
Thirty three primiparae with a singleton fetus and cephalic presentation booked for 
induction of labour because of hypertension or prolonged pregnancy and without evidence of 
placental insufficiency were studied.
The women were entered into the trial on the evening before planned induction if the 
modified Bishop score according to Calder et al (1974) was less than six. Baseline 
observations of blood pressure, temperature and pulse were made, following which a polymer 
pessary designed to release PGE2 0.9mg/hr. was inserted into the posterior vaginal fornix. 
Each woman was then monitored by external cardiotocography for thirty minutes and 
observations of blood pressure, temperature and pulse were continued at hourly intervals for
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two hours. In all women the occurrence of contractions and established labour overnight were 
recorded.
Approximately 14 hours later the cervical state was reassessed in all women. Women 
who had not established labour overnight were then randomly allocated using a predetermined 
code contained in individual envelopes to receive either amniotomy and a titrated infusion of 
oxytocin starting at 2mu/min increasing to a maximum of 48mu/min as necessary to establish 
labour, or a further polymer pessary followed six hours later by amniotomy and oxytocin 
titration if labour was not established. Subsequent management of labour was conducted by 
the duty delivery suite staff.
This study was discontinued after recruitment of 33 women following withdrawal of 
the controlled release polymer pessary by the manufacturers because of concern about rapid 
labours reported by some clinical units. Sixty nulliparae were to be recruited since prior 
calculations had indicated that this would be the required sample size for a 90% power of 
detecting an eight hour difference in the mean prostaglandin to delivery interval at the 5% 
level for patients requiring second treatments prior to establishing labour.
6.3 RESULTS
Thirty three primiparae were studied with a mean ± sd age of 27.6 =*= 5.9 years and a 
mean ± sd gestation of 40.2 ±1.2 weeks.
The outcome of labour for 17 patients labouring after one prostaglandin treatment is 
shown in table 16.
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TABLE 16: LABOUR OUTCOME FOR WOMEN COMMENCING
LABOUR OVERNIGHT
N =  17
CHANGE IN BISHOP SCORE 7.0 ±  1.8
PROSTAGLANDIN TO DELIVERY 
INTERVAL (h) 13.9 ± 5 .4
FIRST STAGE (b) 6.7 ±  3.8
EPIDURAL ANALGESIA 8
MAXIMUM RATE OF OXYTOCIN 
(nyz/min)
12.0 ±
(n  =  4)
MODE OF DELIVERY 
Spontaneous 
Vaginal operative 
Section
12
5
0
UMBILICAL BLOOD pH 
Artery 
Vein
7.18 ± 0 .0 8  
730 ±  0.04
BIRTHWEIGHT (Kg) 3 3  ±  0 3
APGAR SCORE AT 1 MIN
0 - 3 
4 - 7  
8-10
2
6
9
APGAR SCORE AT 5 MIN 
0 - 3 
4 - 7  
8-10
1
1
15
values are totals or means ± sd
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All patients delivered vaginally and four received oxytocin augmentation while eight 
required epidural analgesia. Two patients experienced uterine activity necessitating pessary 
removal. Painful strong uterine contractions occurred in one patient one hour following 
pessary insertion at a frequency of one contraction every two minutes and were associated 
with a fetal tachycardia. The pessary was removed one hour later and the intensity and 
frequency of the contractions diminished during the following hour without further treatment. 
The baby was bom by spontaneous vaginal delivery with Apgar scores of 8 at one minute and 
10 at five minutes. The other patient experienced strong painful contractions at a frequency of 
one contraction in every two minutes both at one hour following pessary insertion for a 
period of twenty minutes and at four hours following pessary insertion at which time the 
pessary was removed. The baby was delivered by forceps and was discoloured by meconium: 
Apgar scores were 4 and 10 at one and five minutes respectively. Neither patient had ruptured 
membranes prior to the onset of painful contractions.
One fetal death occurred following induction of labour for hypertension in a 35 year 
old primiparous woman at 39 weeks gestation. Previously during the pregnancy, her diastolic 
blood pressure had been recorded at 100 mm Hg but was recorded as 140/85 on admission. 
There were no other signs ofpre eclampsia and umbilical doppler recordings had been normal. 
Cervical assessment at 1900 hours demonstrated a Bishop score of three and a pessary was 
inserted into the posterior vaginal fomix. Continuous fetal heart monitoring for one hour 
following pessary insertion was interpreted as being entirely satisfactory by medical staff, and 
it was repeated at 23.05 hours for a further 30 minutes which was also reported as entirely 
satisfactory. At 0200 hours the patient awoke with some lower suprapubic discomfort which 
was described as constant but cramp-like and at 0300 she called the midwife , at which time 
the fetal heart was not listened to. Ten minutes later the midwife returned to find the patient 
asleep and she therefore did not disturb her. At 0500 hours the patient awoke with regular 
contractions and requested analgesia. At this time the fetal heart could not be detected and 
shortly after transfer to delivery suite, fetal death was confirmed by ultrasound scanning. 
Labour continued and an amniotomy was performed at the onset of second stage at 0900
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hours. A fresh stillbirth was delivered at 0920 and at delivery the cord was found wrapped 
tightly around the left upper arm of the fetus.The pessary was not found at birth.
The postmortem examination of the baby was normal and the birthweight was 
3.207kg. There was no evidence of placental separation or of a retroplacental bleed.
One other neonate was bom with Apgars scores of 3 at one minute and 5 at five 
minutes. The mother had received pethidine two hours prior to delivery. The baby responded 
to facial oxygen and the 10 minute apgar score was 9. All other neonates were discharged 
from the unit without intervening complications.
The outcome of labour for 16 patients requiring a second procedure is shown in table
17.
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TABLE 17: LABOUR OUTCOME FOR PATIENTS NOT ESTABLISHING
LABOUR AFTER INITIAL PROSTAGLANDIN TREATMENT■
CHANGE IN BISHOP SCORE 15 ± 1.6
PROSTAGLANDIN TO DELIVERY 
INTERVAL (h) 245 ±7.1 25.4 ±4.8
2nd TREATMENT TO DELIVERY 
INTERVAL (h) 10.4 ± 45 14.9 ± 5.6
EPIDURAL ANALGESIA 4 (50%) 7 (99%)
MAXIMUM RATE OF OXYTOCIN 
(nyi/min)
303 ± 113 
(n = 8)
31.1 ±  14.8 
(n =  7)
MODE OF DELIVERY
Spontaneous 2 2
Vaginal operative 3 3
Section 3 3
UMBIUtALpH
Artery
Vein
7.25 ± 0.03 
732 ±0.05
735 ± 0.07 
732 ± 0.05
BIRTHWEIGHT (Kg) 3.6 ± 0 .4 33±  03
APGAR SCORE AT 1 MIN 
0 - 3 0 0
4 - 7 1 1
8-10 7 7
APGAR SCORE AT 5 MIN 
0 - 3 0 0
4 - 7 0 0
8-10 8 8
values are totals or means ± sd
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The mean ± sd change in Bishop score for these patients following initial prostaglandin 
treatment was 1.5 ± 0.5. None of the patients who required a second procedure complained of 
uncomfortable uterine contractions following treatment with the initial pessary.
There were no differences in the prostaglandin to delivery interval between the two 
groups but the mean ± sd second procedure to delivery interval of 10.4 ± 4.5 hrs for patients 
receiving oxytocin was shorter than 14.9 ± 5.6 hrs for patients receiving a second polymer 
pessary (p= 0.1 students t test). Seven (88%) patients in the 2nd pessary group required 
epidural analgesia compared with four (50%) in the oxytocin group (NS. Fisher exact test) and 
seven (88%) patients in the 2nd pessary group subsequently required oxytocin augmentation. 
Three (38%) patients in each group were delivered by Caesarean section compared to none of 
the patients who laboured following insertion of the first polymer pessary (p< 0.05 Chi square 
test).
The prostaglandin to delivery interval for all patients is illustrated in figure 20. There 
were no significant differences in mean prostaglandin to delivery intervals for those treated 
with the polymer pessary compared to those treated with the 2mg prostaglandin gel in section 
7 (N. S. Students t test).
There were no neonatal complications prior to discharge in any of the women in either 
group. All neonates were bom with five minute Apgar scores of eight or more.
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\SECTION 7: PROSTAGLANDIN INDUCED CERVICAL RIPENING UNDER 
TOCOLYTIC COVER IN PRIMP ARAB : RESULTS OF A DOUBLE BLIND 
PLACEBO CONTROLLED TRIAL
7.1 INTRODUCTION
It has already been shown that oral administration of tocolytics prior to vaginal 
prostaglandins appears to suppress both prostaglandin induced uterine contractions (Goeschen 
et al 1985), and the onset of labour(Insull et al 1989), whilst allowing cervical ripening to take 
place. The outcome of labour did not appear to be adversely influenced in either study, 
indicating that this approach to labour induction may have advantages in cases where placental 
insufficiency is suspected. To explore this concept objectively, a double blind placebo 
controlled study was conducted in primiparae with an unnpe cervix requiring labour induction, 
to determine the effects upon cervical ripening, labour progress, and neonatal outcome.
7.2 METHODS
Sixty nulliparae with a singleton fetus and cephalic presentation booked for induction of 
labour because of hypertension or prolonged pregnancy, and without evidence of placental 
insuffidency, were recruited to the study
Patients were entered into the trial on the evening before planned induction. Cervical 
acsMcment was performed and if the Bishop score was less than 6, baseline observations of 
blood pressure, temperature, and pulse were made, and a blood sample collected from a vein 
in the antecubital fossa for salbutamol analysis, following which external cardiotocography 
was commenced. Each patient was then randomly allocated to receive either salbutamol 8mg 
(Ventolin Spandets: Allen & Hanburys) or identical placebo orally according to a 
predetermined code kept in the pharmacy and not broken until completion of the study. Thirty 
minutes later prostaglandin E2 (PGE2) 2mg gel (Prostin E2 vaginal gel: Upjohn) was instilled 
into the posterior vaginal fornix. Maternal pulse rate was recorded at thirty minute intervals
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for a further 90 minutes, at which time cardiotocography was discontinued, and a further 
blood sample taken for salbutamol analysis. In all patients any symptoms attributable to 
salbutamol and the occurrence of contractions, or established labour overnight were 
recorded.
Approximately fourteen hours later, the same clinician reassessed the cervical state 
without reference to the previous cervical score on those patients not labouring overnight. 
Low amniotomy was then performed when sufficient cervical dilatation had taken place, and a 
titrated infusion of oxytocin started one hour later at 2mu/min increasing to a maximum of 
48mu/min as necessary to establish labour. Where amniotomy was not possible, further 
treatment with either prostaglandin or a titrated infusion of oxytocin was commenced, and 
amniotomy performed when cervical dilatation was adequate.
Subsequent management of labour was conducted by the duty delivery suite staff. At 
birth, umbilical artery and vein blood gas analyses were performed; in addition a blood 
sample was collected from the umbilical vein, and a further maternal blood sample obtained for 
salbutamol concentration assay. Salbutamol concentrations were determined by solid phase 
extraction and high performance liquid chromatography (Pickup & Harrison 1987).
7.3 RESULTS
Patient details relating to age, height, weight, gestation, and Bishop score before 
treatment are shown in table 18. There were no statistical differences between the two groups 
(N. S. Students t test).
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TABLE 18 CHARACTERISTICS OF THE WOMEN IN THE STUDY
Salbutamol
(” = 31)
Placebo 
(n = 29)
Age (years) 24.5(4.8) 25.3(4.6)
Gestation (weeks) 40.9(1.0) 40.7(1.2)
Maternal weight (kg) 77.6(10.7) 80.1 (10.1)
Maternal height (m) 1.6(0.05) 16(0.1)
No. of women with pre-treatment 
Bishop scores 
1-2 8 5
3-5 23 24
Results are mean (SD) values
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The effects of salbutamol are shown in table 19. The mean ± sd number of contractions 
recorded over a 10 minute period on the tocograph before treatment with salbutamol or 
placebo and two hours after treatment were not significantly different in either group. 
However, uterine contractions were experienced during the night by 20 (64%) patients in the 
salbutamol group, compared with 26 (90%) in the placebo group (p < 0.05 Chi square test). 
Eleven(35%) patients treated with salbutamol commenced labour overnight compared with 18 
(62%) treated with placebo (0. l>pX).5). Headache or vomiting was experienced by 10% 
patients treated with salbutamol compared with none treated with placebo.
The mean (sd) change in cervical score for salbutamol treated patients was 3.0 ± 3.1 
compared with 5.8 ± 3.2 for the placebo treated patients (p< 0.05 Students t test). For the 20 
non labouring patients in the salbutamol group, the mean cervical change of 1.5 ± 1.7 was also 
significantly less than 2.9 ± 1 .6  for the 11 non labouring placebo group (p< 0.05). Nine 
patients treated with salbutamol had a change of one or less in cervical score and required 
further treatment before induction of labour, compared with only two in the placebo group 
(0.1>p>0.05 Chi square test).
In the salbutamol group, the mean ± sd maternal plasma salbutamol concentration two 
hours following treatment was 4.74 ± 3.58ng/ml, and following delivery was 1.49 ± 1.48ng/ml 
while the umbilical vein concentration at delivery was 1.55 ± 1.26ng/ml. There was no 
association between salbutamol levels and side effects from salbutamol, or the occurrence of 
contractions, pain, or establishing labour during the night. Salbutamol was not detected in any 
of the plasma samples of the placebo group.
The outcome of labour and neonatal condition are shown in table 20. The mean (±sd) 
pessary to delivery time for salbutamol treated patients of 26.1 ± 6.49 hours was significantly 
longer than 19.3 ± 7.95 hours in the control group (p<0.05 Students t test). Pessaiy to 
delivery times for each group are illustrated in figure 20.
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TABLE 19 EFFECTS OF SALBUTAMOL DURING 
CERVICAL RIPENING
Salbutamol 
{n — 31)
Placebo 
(n -2 9 )
No. of contractions/10 min on cardiotocograph 
Before salbutamol 
2h after salbutamol
1.2 (1.1) 
2.7 (1.2)
1.3 (1.1) 
3.0 (1.5)
No. of women with contractions overnight 20(64%) 26 (90%)
No. of women with onset of labour overnight 11 (35%) 18(62%)
No. requiring more oxytocin before amniotomy 9(23%) 2(7%)
Change in Bishop score 
All women
Women without onset of labour
3.0 (3.1) 
1.5 (1.7)
5.8(32)
2.9(16)
Results are means (SD) or n (%) as appropriate.
132
TABLE 20 OUTCOME OF LABOUR IN THE STUDY GROUPS
Salbutamol 
(” =  31)
Placebo 
(« =  29)
Pmstaglandm-to-deliveiy interval* (h) 
All women 26.1(6.49) 19.3(7 .95)
Women without onset of labour overnight 29.0(4 .8) 2 5 .4 (5 .2  )
First stage (h) 8.2 (3.8) 7.5 (4.1 )
First stage > 10 h 11 5
Maximum rate of oxytocin (mu/min) 24.6(11.0) 22.4 (15.8)
(/I —18) (” =  15)
Mode of delivery
Spontaneous 16(51%) 16(55%)
Forceps 12 (39%) 10(35%)
Section 3(10%) 3 (10%)
Umbilical Wood pH
Artery 7.21 ( 1.0) 7 .1 9 (0 .8 )
Vein 7.31(0 .7 ) 7 .2 9 (0 .8 )
Birthweight (g) 3477 (436) 3329(746)
Apgar score al l min
1-4 3 1
5-7 3 5
8-10 25 23
Apgar Score at 5 min 
1-4 0 0
5-7 1 0
8-10 30 29
♦Three women (one in the salbutamol and two in the placebo group) who were 
not induced the next day are excluded from this analysis.
Results are means (SD) or n (%) as appropriate.
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Figure 20 Cumulative percentage 
deliveries with time after vaginal 
prostaglandin administration
100'o
prostaglandin gel and placebo 
prostaglandin gel and salbutamol
polymer pessary
5 0 -
2 5 -
20 30 40 50100
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The first stage of labour was longer than 10 hours in eleven patients treated with salbutamol 
compared with five patients receiving placebo (0.2>p>0.1 Chi square test), and 20 patients 
(65%) in the salbutamol group required epidural analgesia compared with 11 (39%) in the 
placebo group (0.1>p>0.05). Three patients in each group were delivered by caesarean 
section: two for failure to progress and one for fetal distress in the salbutamol group, and one 
for failure to progress, and two for fetal distress in the placebo group. There was a retained 
placenta in one patient treated with salbutamol, and three patients in each group sustained an 
estimated blood loss of 500 - 1000 ml during or immediately following the third stage of 
labour: one placebo treated patient had an inverted uterus in the third stage of labour with 
2000 ml blood loss, the uterus being repositioned and the patient transfused.
Induction of labour was not possible the following day in three patients, but all were 
later successfully induced. One of these patients who had received salbutamol was delivered 
by caesarean section for fetal distress after five hours in the first stage of labour, whilst the 
remaining two patients, both in the placebo group, delivered spontaneously.
There were no neonatal complications prior to discharge in any cases studied. Apgar 
scores at five minutes were eight or greater in all neonates except one in the salbutamol group. 
Thick meconium was noted at the birth of this baby who was immediately intubated to ensure 
the upper airway was cleared and the ten minute apgar score was nine.
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SECTION 8:DISCUSSION
There are a number of variables which determine the responses of uterine muscle to 
vaginal administration of prostaglandin. These include the total amount and rate of 
prostaglandin release, its rate of absorption across the vaginal epithelium, sensitivity of uterine 
muscle to prostaglandin and the rate of its metabolism to inactive metabolite. Controlled 
release of prostaglandin from the polymer pessary provides the ability to control the amount 
and rate at which prostaglandin is released which may be seen as beneficial in labour induction.
Previous research has shown that release profiles of the polymer pessary in vitro may 
be accurately predicted for a range of polymer compositions and follow a similar pattern 
(McNeill & Graham 1984): the release ofPGE^ from an initially dry pessaiy is approximately 
constant until the time of half life and then continues at a decreasing rate. Methodology in that 
work involved placement of the polymer pessary in 25mls of low salt phosphate buffer 
solution which was regularly exchanged for fresh buffer, thereby providing a dynamic 
environment where diffusion ofPGE^ from the pessary was not inhibited by PGE^ already in 
solution. Although the studies in sections 5.1 and 5.2 were based on different methodology, 
the results of m vitro release were similar with a slowly decreasing release rate throughout the 
observation period. This suggests that any inhibition to PGE^ release that may have occurred 
as the concentration ofPGE^ in the surrounding saline increased was relatively insignificant. 
The differences between the patterns ofPGE^ release in vivo and in vitro cannot therefore be 
fully explained by this factor and are likely to be primarily related to the degree of hydrogel 
swelling. As the hydrogel takes up fluid the crystallites dissolve, resistance to diffusion 
decreases, and drug release becomes approximately constant or zero order (McNeill & 
Graham 1984). Once fully swollen, drug release continues at a decreasing rate where release is 
proportional to the square root of time. There was significantly less hydrogel swelling in vivo 
which might explain why release was initially slower than in vitro and why a point of 
decreasing release rate was not reached, allowing more PGE2 to be available for vaginal 
absorption in the latter part of the observation period.
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Vaginal insertion of a partially hydrated pessaiy was associated with a rate of hydrogel 
swelling which did not significantly inhibit PGE2 release from pessary A, although there was 
still more fluid uptake in vitro than in vivo. Pre-soaking the pessary made little overall 
difference to the pattern of fluid uptake in vivo and was not associated with any obvious 
improvement in predictability of PGE2 release. A longer pre-soaking period may have resulted 
in more predictable PGE2 release and release of PGE2 during that time could have been 
prevented by pre-soaking in a solution of PGE2. However once the pessary is fully swollen, 
the release rate of PGE2 would alter by decreasing exponentially with time instead of 
following zero order kinetics (McNeill & Graham 1984).
By designing the studies to comply with normal delivery suite protocol, it was possible 
to observe the hitherto unpredicted effects of amniotomy on PGE2 release from the pessary in 
vivo. The PKa of prostaglandin is 4.9 so that individual variation in the pH of the vagina may 
affect the solubility of PGE2.which has been shown to increase from less than 5mg/ml at pH 
5.0 to 70mg/ml at pH 5.5.(Stehle 1982) The mean vaginal pH at term is 4.09 (sd 0.52) 
(Gleeson et al 1989). but amniotomy performed while the pessary is in situ provides an 
alkaline environment which may serve to increase the solubility of PGE2 as well as providing 
enough fluid to increase the rate of hydrogel swelling in vivo. The results for pessary B 
suggest that these factors may contribute to increased PGE2 release as the calculated hourly 
release rate was higher in cases where an amniotomy was performed prior to vaginal 
insertion. A recent study of release characteristics of the polymer pessaiy in vitro supports 
these findings (Johnson et al 1992). The pessary was placed in 3 different solutions of Ringers 
lactate at pH values of 3.4, 5.4,and 7.4 and release of PGE2 was measured over 12 hours. 
PGE2 release doubled during the first 6 hours of the observation period as the pH of the 
solution increased from 3.4 to 7.4.However there is a maximum rate of drug release from the 
polymer pessary which is defined by physical laws and cannot be exceeded (Graham 1990). 
These observations indicate that the pessary should be removed prior to amniotomy or 
following spontaneous rupture of membranes.
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increase in the later stages of cervical ripening (Fuchs et al 1984). The relationship may not 
have been observed as there was little change in cervical score in a number of patients.
More predictable results may have followed a longer interval between administration 
of PGE2 and reassessment of the cervix but in section 6 the onset of labour was not effectively 
delayed while allowing cervical ripening to take place. 52% of women treated with the pessary 
commenced labour overnight which is similar to the incidence of labour reported in the 
prostaglandin gel group in section 7, confirming the similar efficacy of the two preparations. 
The onset of labour may have been delayed by the use of a pessary with a slower release 
profile but there is presumably a rate of prostaglandin release below which the cervix will fail 
to respond. Alternatively a lower total dose of prostaglandin may have achieved the same 
effect.
In the clinical trial with the polymer pessary, women responded in two distinct ways to 
treatment either establishing labour or having a comfortable night with little improvement in 
Bishop score. Women who required a second procedure prior to the establishment of labour 
appeared to respond more favourably to the use of amniotomy and oxytocin than to repeated 
prostaglandin treatment: the second procedure to delivery time was shorter and less epidural 
analgesia was required in this group but the small numbers involved prevented detection of 
any significant differences. In a previous trial of similar design but using endocervical 
prostaglandin gel it was observed that 59% of women treated with repeat doses of the gel 
formulation were not delivered within 24 hours of the start of treatment compared to 40% 
receiving oxytocin titration following prostaglandin gel (Keirse et al 1987). Labour outcome 
was otherwise similar to the present study but the results suggest that once the cervix has been 
exposed to prostaglandin there may be little benefit from repeated administration, although the 
dose of prostaglandin necessary to prime the cervix initially may vary between individuals. 
Women who required further treatment prior to the establishment of labour were also more 
likely to require a Caesarean section, an observation supported by previous work (MacKenzie 
1981).
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The non-biodegradable properties of the polymer pessary make its use in labour 
induction particularly attractive as this permits removal of the prostaglandin source in the 
event of an adverse reaction. However technical difficulties were experienced with pessary 
recovery due to its slippery nature and adherence to the vaginal wall sometimes causing 
unacceptable discomfort to the patient. Others have since experienced similar problems (Bex 
et al 1990). A significant number of pessaries were also spontaneously expelled from the 
vagina either with amniotic fluid or at micturition and those expelled at delivery were 
sometimes lost in the accompanying blood and liquor. As a result not all pessaries were 
retrieved and the possibility of maternal retention could not always be ruled out. A more 
sophisticated retrieval mechanism is warranted and a retrieval "net" has recently been 
developed. The upper portion of the net is designed for the pessary and is composed of 
polyester which can stretch as the pessary swells. The lower portion is composed of polyamine 
which is non-elastic in nature and prevents the pessary from being expelled from the net. A 
recent study on the acceptability and efficacy of the retrieval system found that the pessaiy 
could be removed with no or only slight difficulty in 97% cases. However the pessary was still 
lost in 11 out 111 cases following labour (Westgate & Williams 1996). Studies of the release 
characteristics of the pessary within the retrieval mechanism are required to confirm that the 
net does not interfere with PGE2 release.
One case of excessive uterine activity which warranted pessaiy removal was observed 
in section 5 and two cases were observed in section 6 which is equivalent to an incidence of 
3.7%.In section 6 release of PGE2 from pessary A was less than the predicted release profile, 
but the patient also received pessary B where the release profile was greater than expected. 
Pessary B had been swollen in vitro for four hours and an amniotomy performed before its 
insertion vaginally, both of which may have been contributory to more rapid PGE2 release and 
subsequent excessive uterine activity. The maximum rise in PGEM levels of 662pg/ml in this 
case was not the greatest increase observed during the studies. The prostaglandin effects may 
simply be related to individual sensitivity to PGE2 or alternatively might be related to a
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superimposed effect o f V G ^ cl. Uterine tissues are thought to possess low affinity PGF 
binding sites and high affinity PGE binding sites (Giannopoulos et al 1985, Adelantado et al 
1988). It has been suggested that the PGF binding sites are not specific receptors so that any 
actions ofPGF^ may be mediated through PGE receptor sites (Schillinger & Prior 1976). If 
such a mechanism exists, any increase in PGF levels while the uterus is still being exposed to 
exogenous PGE^ may contribute to the possibility of excessive uterine activity. Such a 
mechanism could be avoided by removal of the source of exogenous PGE^ once labour is 
established.
Two women who laboured overnight in section 6 experienced excessive uterine 
activity which warranted removal of the pessary. Neither patient had ruptured membranes at 
the time of pessary removal so that any interference in prostaglandin release through rapid 
hydrogel swelling of the pessary by amniotic fluid is not an explanation. In both cases 
excessive uterine activity settled spontaneously within an hour of pessary removal. The 
possibility that controlled release of prostaglandin causes a cumulative increase in circulating 
prostaglandins in some women must be considered although studies on the metabolism of 
prostaglandin suggest that this is unlikely (Ferreira & Vane 1967).
Hyperstimulation has been shown to complicate < 7.3% of labours induced with other 
vaginal prostaglandin preparations (Egarter et al 1990) and one of the advantages of the 
controlled release preparation may be a reduced incidence of hyperstimulation as suggested by 
these studies. The 7.0% to 15.0% incidence of rapid labours reported by others (Khouzam & 
Ledward 1990, Miller et al 1991, Rayburn et al 1992, Witter et al 1992) is therefore 
surprising. In Khouzam and Ledward's cases, one appears to be irrelevant as there was no 
mention of labour having started. Cervical score was not mentioned in the other two cases and 
both patients were multiparous. Careful cervical assessment is essential before treatment with 
prostaglandins in any form and is probably best avoided when the cervix is ripe (Bishop score 
> 8). It was concluded that "dose dumping" in vivo was frequent but without any evidence of 
in vivo release profiles. The results from section 5.1 and 5.2 indicate that "dose-dumping" of
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prostaglandin might play a role in situations where PGE2 release from the pessary is increased 
by amniotic fluid but there is no evidence for rapid release in other situations. In the cases 
reported by Rayburn and colleagues and Witter and colleagues, most occurred after the onset 
of labour, and delivery occurred within the 12 hour observation period in 27 of 101 cases 
reported by Rayburn. The effect of amniotomy may have played a role in some of these cases 
as in the two cases described by Miller and colleagues. These results combined with the 
information provided from the in vitro studies on the effects of pH on PGE2 release confirm 
the importance of pessary removal prior to amniotomy or immediately following spontaneous 
rupture of membranes.
There was no evidence to suggest that the polymer pessaiy was a contributing factor 
to the fetal death. The incident was not associated with prostaglandin-induced uterine 
hyperstimulation and studies on other components of the pessary have not revealed any 
evidence of toxicity to humans (Huntingdon Research Centre 1983). There have been no other 
reports of fetal death associated with the use of the pessary. However prostaglandins when 
given vaginally in any carrier vehicle may be associated with fetal distress and their use must 
be treated with care and appropriate maternal and fetal observations made following 
administration. The results of this study and previous trials (Embrey et al 1980, Embrey & 
MacKenzie 1985) suggest that the controlled release formulation is comparable to other 
formulations used in cervical ripening and labour induction.
Tocolytic cover with oral salbutamol in section 7 almost halved the incidence of labour 
occurring following vaginal prostaglandin administration, compared with placebo. The 
incidence of labour in an uncontrolled study of oral tocolysis in a similar group of patients was 
19% (Insull et al 1989): in that study the prostaglandin was given as a vaginal pessary rather 
than viscous gel, which may have influenced the release of prostaglandin. The mechanism of 
action of salbutamol is probably through interference with intracellular calcium channels 
thereby both reducing prostaglandin induced myométrial contractility (Huzar and Naftolin 
1984,Garfield 1984), and adversely influencing endogenous prostaglandin synthesis (Gorraci
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et ai 1978). The incidence of labour starting during the ripening process in the placebo group 
was similar to that previously reported for primiparae with Bishop scores of 5 or less 
(MacKenzie and Embrey 1978, Shepherd era / 1981). The frequency of uterine contractions in 
the first two hours in both groups did not predict the onset of labour which is at variance to 
previous findings (Facchinetti et al 1995).
Salbutamol treatment appears to inhibit prostaglandin induced uterine contractions at 
the expense of cervical ripening, suggesting the importance of myométrial contractility in 
cervical ripening. These results are at variance to the findings of Goeschen et a/(1985) who 
found that oral tocolytics given 30 minutes before FGE^ application to 17 patients with an 
unripe cervix (Bishop score 6 or less) successfully suppressed prostaglandin induced uterine 
contractions without affecting cervical ripening compared with 17 controls. The differences 
might be explained by the fact that their observations were based on cervical assessment 8 
hours following prostaglandin administration in patients of mixed parity, some of whom had 
premature rupture of membranes.
Although prostaglandin induced uterine contractions may be acutely suppressed by 
tocolytics (Maclean and MacKenzie 1980), effective sustained tocolysis was not achieved in a 
substantial minority in this study. Further suppression of contractility is necessary in such cases 
so that the onset of labour is prevented. This may be possible with a larger or repeated 
tocolytic dose: Plasma levels of 8-33ng/ml are necessary to inhibit uterine contractions in 
preterm labour (Hutchings et ai 1987), but this concentration was achieved in only four 
patients, one of whom still laboured during the night. However the poorer outcome of labour 
in salbutamol treated patients mitigates against this approach, and the possibility of an 
increased risk of post-partum haemorrhage following additional betamimetic inhibition of 
myométrial activity must be considered, although there was no evidence of this in the present 
study. Intravenous or intramuscular salbutamol is unlikely to convey any advantage, but local 
administration might be worth exploring, perhaps as a combined preparation.
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By reducing the incidence of labour occurring overnight, salbutamol prolongs the
prostaglandin treatment to delivery time, which might not generally be seen as an attractive
development by women or staff. Nevertheless in those cases with suspected placental
insufficiency, or in cases where intensive neonatal care immediately following delivery is
anticipated such as major structural abnormalities or severe rhesus incompatibility, there are
f
potential benefits in preventing labour occurring overnight, so that a more formal controlled 
induction can be managed when delivery suite and neonatal unit staffing levels are able to 
provide optimum cèhàitions.
SECTION 9: CONCLUSIONS
The following conclusions can be drawn from the studies.
1. Release of PGE2 from the controlled release hydrogel pessary in vitro follows a linear 
and quadratic pattern while release in vivo is described by a quadratic pattern.
2. Differences in release patterns in vitro and in vivo are primarily due to differences in
hydrogel swelling.
3 Less predictable PGE 2 release in vivo may be attributed to the amount of vaginal
cream used in digital asssessment of the cervix, vaginal dryness and mucus content, vaginal pH 
and the effects of amniotomy on pH.
4. Amniotomy performed while the pessary is in situ results in more rapid PGE^ release
because of changes in the solubility of PGE^ at different pH values. The pessary should 
therefore be removed prior to amniotomy or immediately following spontaneous rupture of 
membranes.
5. There are no significant differences in PGE^ release profiles in vivo for pessaries 
designed to release PGE^ 1.0mg/hr and 0.6mg/hr as assessed from in vitro data. Calculated 
hourly release rates for the pessaries ranged from 0.0mg/hr to 2.28mg/hr
6. Removal of the polymer pessary in vivo is associated with a decrease in PGEM
concentrations which should be seen as advantageous in cases of uterine hyperstimulation. 
Further studies are required to ascertain how quickly PGEM levels fall following pessaiy 
removal.
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7. The incidence of hyperstimulation associated with the use of the polymer pessary in 
these studies was 3.7%. Removal of the pessaiy resulted in a return to normal uterine activity 
in all cases.
8. A more sophisticated pessary removal system is required following the difficulties in 
pessaiy removal experienced in these and other studies. 9.9% pessaries are still lost following 
labour using the new retrieval net.
9. Controlled release of prostaglandin is not associated with predictable cervical ripening 
that occurs without the establishment of labour. The performance of the polymer pessary and 
prostaglandin 2mg gel was similar in two consecutive studies using the same methodology.
10. Tocolytic cover during cervical ripening with the prostaglandin gel can suppress 
prostaglandin-induced uterine activity but results in a poorer outcome of labour.
The results from this thesis and other studies suggest that the polymer pessary and 
2mg prostaglandin gel work with similar efficacy. The polymer pessary was designed as a safer 
alternative but can only be regarded in this way under strict criteria which do not apply to the 
use of the prostaglandin gel. The polymer pessaiy should be removed following the onset of 
labour, prior to amniotomy or following spontaneous rupture of membranes. However under 
these conditions and provided that there is no difficulty in removing the pessary, adverse 
events still occur at a similar rate to the use of the prostaglandin gel, which is considerably 
cheaper. There are therefore no compelling reasons to consider the polymer pesssary in its 
current form in preference to the 2mg prostaglandin gel formulation.
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APPENDIX
APPENDIX 1 iDETERMINATION OF PGE2 IN HYDROGEL PESSARIES AND SALINE
SOLUTIONS
A reversed phase high pressure liquid chromatography method (HPLC) incorporating 
post column derivatisation has been developed and validated by Controlled Therapeutics Ltd 
for the quantitation of PGE2 in hydrogel pessaries. The HPLC method utilises a Hypersil 
ODS, 5 micron column, and a mobile phase consisting of acetonitrile, water, triethylamine, 
and perchloric acid, adjusted to pH 4. The post column derivatisation reaction is carried out at 
100 C using a solution of tétraméthylammonium hydroxide. Quantitation is via UV detection 
at 280nm.
The assays were performed by Controlled Therapeutics and the exact details of the 
method are confidential, but the procedure involves thawing of the stored pessaries before 
placement in a 50ml beaker. A small amount of mobile phase is added and when the pessary is 
fully swollen, it is transferred to a Waring blender and ground to a fine powder. The swelling 
solution and the powder are transferred quantitatively to a 200ml volumetric flask using 
mobile phase. The flask is placed in an ultrasonic bath for 5 minutes, then on a flat shaker for 
15 minutes. The flask is adjusted to volume using mobile phase and this solution is injected in 
duplicate on the HPLC. The saline solutions are also injected on the HPLC in duplicate.
Linearity of PGE2
Assay linearity has been established over the range of 20-80pg/ml, equivalent to 
40-160% label content of a lOmg pessary extracted into 200ml of mobile phase. A mean 
recovery of 99.63% and a relative standard deviation of 0.66% were observed. Linear 
regression analysis of the data revealed an intercept not significantly different from zero and a 
correlation coefficient of 0.9998. No statistically significant bias was observed at the 95%
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confidence level. Linearity of response to PGE2 was maintained when a different column was 
used and also when the mobile phase was adjusted to pH 3.5 and 4.5.
Spiked recovery of PGE2
PGE2 recovery studies were performed over the range 50-150% label showing a mean 
recovery of 98.59% and a relative standard deviation of 1.03%. Linear regression analysis 
revealed an intercept not significantly different from zero and a correlation coefficient of 
0.9997. No experimental or statistically significant bias were observed at the 95% confidence 
level.
Precision study
Ten replicate assays of the formulation run over two days resulted in a mean assay of 
10.27mg PGE2 per pessary and an overall relative standard deviation of 2.08%.
Limit of detection and quantitation of PGE2
The method was found to be linear and quantifiable down to the limit of detection for 
PGE2 which is 0.27pg/ml, equivalent to 0.05mg/pessary.
The method was shown to separate PGE2 from its known degradation products as 
shown by the retention times given below.
Specificity
p g e 2
p g a 2
p g b 2
COMPONENT RETENTION TIME (MIN)
3.3
5.6
8.2
15-KETO PGE2 4.0
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APPENDIX 2: PATIENT INFORMATION SHEETS
The following two pages are examples of information sheets used in sections 6 and 7 
respectively.
□
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PATIENT INFORMATION SHEET
O bserva tions  on th e  u se  of th e  c o n t r o l l e d  r e l e a s e  PGE2 p e ss ry  fo r  c e r v ic a l
r ip e n in g  and lab o u r in d u c t io n
The d e c is io n  has  been reached  t h a t  your lab o u r  w i l l  b e jinduced and t h i s  
w i l l  be performed u s in g  a p e s s a ry  c o n ta in in g  some p r o s ta g la n d in s  (a hormone) 
p laced  in  your v ag ina .
A new form of p e s s a ry  has  been developed t o  t r y  t o  improve th e  r e s u l t s  we 
o b ta in  inducing  la b o u r  in  t h i s  way. We a re  i n v i t i n g  you t o  t a k e  p a r t  i n  a  . 
small s tu d y  to  m onitor t h e  changes t h a t  occur in  your c e rv ix  and th e  outcome 
of your lab o u r  fo l lo w in g  th e  a d m in is t r a t io n  of th e  p ro s ta g la n d in  p e ssa ry .  The 
c a re  we p rov ide  f o r  you w i l l  be t h e  same a s  t h a t  c u r r e n t l y  used in  t h e
Department when o th e r  p e s s a r i e s  o r  g e l s  a re  used f o r  t h i s  pu rpose . We w i l l
p rov ide  a l l  ro u t in e  c a r e  t o  bo th  you and your baby d u r in g  t h i s  tim e and d u r in g  
your subsequent la b o u r .  There a r e  no reco g n ised  a d d i t io n a l  r i s k s  to  th e  form 
of p e s s a ry  t h a t  we a r e  u s in g  a s  judged by e x p e r ien c e  w ith  over 400 p a t i e n t s  
t r e a t e d  w ith  t h i s  p r e p a r a t io n ;  v e ry  o c c a s io n a l ly  p a t i e n t s  have noted some 
burning  in  th e  vagina  f o r  th e  f i r s t  20 t o  30 m inutes  a f t e r  t re a tm e n t ,  a l th o u g h
t h i s  does no t seem t o  be a problem w ith  t h i s  form of p e s s a ry .
You a re  a t  l i b e r t y  t o  r e f u s e  t o  jo in  th e  s tu d y , o r  t o  withdraw a t  any 
tim e and th e  c a re  we w i l l  p ro v id e  f o r  you w i l l  n o t  in  any way be a f f e c te d .
Thank you fo r  a g re e in g  to  c o n s id e r  t h i s  i n v i t a t i o n .
Mr. I .Z .  MacKenzie 
N u ff ie ld  Dept, of O b s te tr ic s .
& Gynaecology 
John R a d c l i f f e  M a te rn ity  H o sp i ta l  
Headington 
Oxford 
0X3 9DU
Dr. Adrian T aylor * *.
N u f f ie ld  Dept, of O b s te t r ic s  
& Gynaecology -
John R a d c l i f f e  M ate rn ity  H o sp i ta l  
Headington 
Oxford 
0X3 9DU
T el: Work: Oxford 817687 
Home: Ick fo rd  405
T el: Work: Oxford 817687 
Home: Oxford 726921
Dear
Yours s i n c e r e l y .
I .Z .  MACKENZIE, MD, FRCGG
C o n su ltan t  O b s te t r ic i a n  & G ynaeco log is t
A. TAYLOR, MB, BS 
Research Fellow
CENTRAL OXFORD RESEARCH ETHICS COMMITTEE PROJECT NO.
152
PATIENT INFORMATION
F u r th e r  o b s e r v a t io n s  on th e  c l i n i c a l  r e s u l t s  of th e  c o n t r o l l e d  r e l e a s e  v ag ina l
p ro s ta g la n d in  p e ssa ry .
Mr. I .Z .  MacKenzie,
N u ff ie ld  Dept, of O b s t e t r i c s  
and Gynaecology,
John R a d c l i f e  M ate rn ity  H o s p i ta l ,  •
Headington,
Oxford.
0X3 9DU.
Tel: Work: Oxford 817687 
Home: Ick fo rd  465
Dear
The d e c is io n  has been reached  t h a t  your labour  w i l l  be induced and t h i s  
w i l l  be performed us in g  a p essa ry  co n ta in in g  some p r o s ta g la n d in s  (a  hormone) 
p laced  in  your vag ina .
He a re  i n v i t i n g  you to  p a r t i c i p a t e  in t h i s  s tudy  to  d e te rm in e  whether a 
second p r o s ta g la n d in  p e ssa ry  a t  th e  tim e your w aters  a re  a r t i f i c i a l l y  broken 
i s  as  e f f e c t i v e ,  o r  more e f f e c t i v e  th a n ,  us ing  th e  commonly p re s c r ib e d  d r ip  
method. The d e c is io n  to  g ive  you a second p ro s ta g la n d in  p e ssa ry  o r  use  the  
d r ip  method w i l l  be dec ided  by th e  t o s s  of a c o i n '  so t h a t  we can a n a ly s e  th e  
outcome f o r  a l l  th e  m others who agree to- help  us  with th e  s tudy  w ithou t any 
b ia s  in  t r e a tm e n t .  We s h a l l  p rov ide  you and your baby w ith  a l l  th e  r o u t i n e  
c a re  t h a t  i s  c u r r e n t l y  p ro v id ed , and w il l  n o te  th e  r e s u l t s  of your la b o u r  to  
enab le  us t o  reach  a c o n c lu s io n .
You a re  under no o b l ig a t io n  to  ag ree  to  p a r t i c i p a t e  in  th e  s tu d y  and you 
can withdraw from i t  a t  any t im e. In both s i t u a t i o n s  your c a re  w i l l  n o t  in  
any way be a f f e c t e d .
Thank you fo r  c o n s id e r in g  involved in  t h i s  small p i e c e  of r e s e a rc h .
Yours s in c e r e ly ,
Dr. Adrian Taylor 
N u ff ie ld  Dept, of O b s t e t r i c s  
and Gynaecology,
John R a d c l i f f e  M a te rn i ty  H o s p i ta l ,  
Headington,
Oxford.
0X3 9DU.
Tel: Work: Oxford 817839 
Home: Oxford 726921
I .Z . MacKenzie, MD, FRC06
C o n su ltan t  O b s t e t r i c i a n  & G ynaecologist
A. T a y lo r , MB, BS 
Research Fe llow
APPENDIX 3
Bishop Score
The Bishop score is determined by a digital assessment of cervical dilatation, consistency, 
effacement, position and descent of the fetal presenting part. It is calculated from the 
following scoring system. |
Points 0 1 2 3
Dilatation 0 1-2 3-4 5-6
Effacement 0-30% 40-50% 60-70% 80%+
Station -3 -2 -1/0 +1/+2
Consistency Firm Med Soft
Position Post Mid Ant
Apgar Score
The Apgar score is used as measure of fetal well-being at birth and is calculated from the 
following scoring system.
Heart Rate >100 2
<100 1
Absent 0
Respiratory Effort Regular 2
Irregular 1
Absent 0
Muscle Tone Normal with movement 2
Normal no movement 1
Limp 0
Colour of Trunk Pink 2
Blue 1
White 0
Response to Stimuli Cry 2
Grimace 1
None 0
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